Glomerular Diseases

Section 2 - Glomerular Diseases

Published online by Cambridge University Press: 10 August 2023

Edited by

Helen Liapis

Show author details

Helen Liapis: Affiliation:
Ludwig Maximilian University, Nephrology Center, Munich, Adjunct Professor and Washington University St Louis, Department of Pathology and Immunology, Retired Professor

Book contents

Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Type: Chapter
Information: Pediatric Nephropathology & Childhood Kidney Tumors , pp. 27 - 180

DOI: https://doi.org/10.1017/9781108907224 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Chang-Chien, C., Chuang, G. T., Tsai, I. J., Chiang, B. L., Yang, Y. H.. A large retrospective review of persistent proteinuria in children. J Formos Med Assoc 2018;117:711–19.CrossRef Google Scholar PubMed

Jang, K. M., Cho, M. H Clinical approach to children with proteinuria. Child Kidney Dis 2017;21:53–60.CrossRef Google Scholar

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012;2:139–74.Google Scholar

Barisoni, L., Schnaper, H. W., Kopp, J. B.. A proposed taxonomy for the podocytopathies: A reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol 2007;2:529–42.CrossRef Google Scholar PubMed

Stone, H. K., Parameswaran, S., Eapen, A. A., Chen, X., Harley, J. B., Devarajan, P., et al. Comprehensive review of steroid-sensitive nephrotic syndrome genetic risk loci and transcriptional regulation as a possible mechanistic link to disease risk. Kidney Int Rep 2020;16;6:187–95.Google Scholar

Farquhar, M. G., Vernier, R. L., Good, R. A.. An electron microscope study of the glomerulus in nephrosis, glomerulonephritis, and lupus erythematosus. J Exp Med 1957;106: 649–60.Google Scholar

Maas, R. J., Deegens, J. K., Wetzels, J. F.. Permeability factors in idiopathic nephrotic syndrome: Historical perspectives and lessons for the future. Nephrol Dial Transplant 2014;29:2207–16.CrossRef Google Scholar PubMed

Podesta, M. A., Ponticelli, C.. Autoimmunity in focal segmental glomerulosclerosis: A long-standing yet elusive association. Front Med (Lausanne) 2020;7:604961.Google Scholar

Wen, Y., Shah, S., Campbell, K. N.. Molecular mechanisms of proteinuria in focal segmental glomerulosclerosis. Front Med (Lausanne) 2018;5:98.CrossRef Google Scholar PubMed

Vivarelli, M., Massella, L., Ruggiero, B., Emma, F.. Minimal change disease. Clin J Am Soc Nephrol 2017;12:332–45.Google Scholar

Chanchlani, R., Parekh, R. S.. Ethnic differences in childhood nephrotic syndrome. Front Pediatr 2016;4:39.Google Scholar

Banh, T. H., Hussain-Shamsy, N., Patel, V., Vasilevska-Ristovska, J., Borges, K., Sibbald, C., et al. Ethnic differences in incidence and outcomes of childhood nephrotic syndrome. Clin J Am Soc Nephrol 2016;11:1760–8.CrossRef Google Scholar PubMed

Mubarak, M., Kazi, J. I., Lanewala, A., Hashmi, S., Akhter, F.. Pathology of idiopathic nephrotic syndrome in children: Are the adolescents different from young children? Nephrol Dial Transplant 2012;27:722–6.CrossRef Google Scholar PubMed

Sadowski, C. E., Lovric, S., Ashraf, S., Pabst, W. L., Gee, H. Y., Kohl, S., et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2015;26:1279–89.CrossRef Google Scholar PubMed

Trautmann, A., Bodria, M., Ozaltin, F., Gheisari, A., Melk, A., Azocar, M., et al. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clin J Am Soc Nephrol 2015;10:592–600.CrossRef Google Scholar PubMed

Liapis, H., Romagnani, P., Anders, H. J.. New insights into the pathology of podocyte loss: mitotic catastrophe. Am J Pathol 2013;183:1364–74.CrossRef Google Scholar PubMed

Kriz, W., Shirato, I., Nagata, M., LeHir, M., Lemley, K. V.. The podocyte’s response to stress: The enigma of foot process effacement. Am J Physiol Renal Physiol 2013;304:F333–47.Google Scholar

Chen, Y. M., Liapis, H.. Focal segmental glomerulosclerosis: molecular genetics and targeted therapies. BMC Nephrol 2015;16:101.Google Scholar

Haas, M., Seshan, S. V., Barisoni, L., Amann, K., Bajema, I. M., Becker, J. U., et al. Consensus definitions for glomerular lesions by light and electron microscopy: Recommendations from a working group of the Renal Pathology Society. Kidney Int 2020 98:1120–34.Google Scholar

De Vriese, A. S., Sethi, S., Nath, K. A., Glassock, R. J., Fervenza, F. C.. Differentiating primary, genetic, and secondary FSGS in adults: A clinicopathologic approach. J Am Soc Nephrol 2018;29:759–74.CrossRef Google Scholar PubMed

Tullus, K., Webb, H., Bagga, A.. Management of steroid-resistant nephrotic syndrome in children and adolescents. Lancet Child Adolesc Health 2018;2:880–90.Google Scholar

Rheault, M. N., Zhang, L., Selewski, D. T., Kallash, M., Tran, C. L., Seamon, M., et al. AKI in children hospitalized with nephrotic syndrome. Clin J Am Soc Nephrol 2015;10:2110–18.Google Scholar

Trautmann, A., Vivarelli, M., Samuel, S., Gipson, D., Sinha, A., Schaefer, F., et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2020;35:1529–61.Google Scholar

Buscher, A. K., Beck, B. B., Melk, A., Hoefele, J., Kranz, B., Bamborschke, D., et al. Rapid response to cyclosporin A and favorable renal outcome in nongenetic versus genetic steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2016;11:245–53.CrossRef Google Scholar PubMed

Ranganathan, S.. Pathology of podocytopathies causing nephrotic syndrome in children. Front Pediatr 2016;4:32.Google Scholar

Bonsib., S. M Focal-segmental glomerulosclerosis. The relationship between tubular atrophy and segmental sclerosis. Am J Clin Pathol 1999;111(3):343–8.CrossRef Google Scholar PubMed

D’Agati, V.. Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol 2003;23:117–34.Google Scholar PubMed

D’Agati, V. D., Kaskel, F. J., Falk, R. J.. Focal segmental glomerulosclerosis. N Engl J Med 2011;365:2398–411.Google Scholar

Cossey, L. N., Larsen, C. P., Liapis, H.. Collapsing glomerulopathy: A 30-year perspective and single, large center experience. Clin Kidney J 2017;10(4):443–9.Google Scholar

Smeets, B., Stucker, F., Wetzels, J., Brocheriou, I., Ronco, P., Grone, H. J., et al. Detection of activated parietal epithelial cells on the glomerular tuft distinguishes early focal segmental glomerulosclerosis from minimal change disease. Am J Pathol 2014;184:3239–48.CrossRef Google Scholar PubMed

Vivarelli, M., Moscaritolo, E., Tsalkidis, A., Massella, L., Emma, F.. Time for initial response to steroids is a major prognostic factor in idiopathic nephrotic syndrome. J Pediatr 2010;156:965–71.Google Scholar

Mendonca, C., Oliveira, E. A., Froes, B. P., Faria, L. D., Pinto, J. S., Nogueira, M. M., et al. A predictive model of progressive chronic kidney disease in idiopathic nephrotic syndrome. Pediatr Nephrol 2015;30:2011–20.CrossRef Google Scholar PubMed

Larkins, N. G., Liu, I. D., Willis, N. S., Craig, J. C., Hodson, E. M.. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev 2020;4:CD002290.Google Scholar PubMed

McCaffrey, J., Lennon, R., Webb, N. J.. The non-immunosuppressive management of childhood nephrotic syndrome. Pediatr Nephrol 2016;31:1383–402.Google Scholar

Banerjee, S., Dissanayake, P. V., Abeyagunawardena, A. S.. Vaccinations in children on immunosuppressive medications for renal disease. Pediatr Nephrol 2016;31:1437–48.CrossRef Google Scholar PubMed

Rovin, B. H., Caster, D. J., Cattran, D. C., Gibson, K. L., Hogan, J. J., Moeller, M. J., et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019;95:281–95.Google Scholar

Chua, A., Cramer, C., Moudgil, A., Martz, K., Smith, J., Blydt-Hansen, T., et al. Kidney transplant practice patterns and outcome benchmarks over 30 years: The 2018 report of the NAPRTCS. Pediatr Transplant 2019;23:e13597.Google Scholar

Bouts, A., Veltkamp, F., Tonshoff, B., Vivarelli, M., Members of the Working Group “Transplantation”, “Idiopathic Nephrotic Syndrome” of the European Society of Pediatric Nephrology. European Society of Pediatric Nephrology survey on current practice regarding recurrent focal segmental glomerulosclerosis after pediatric kidney transplantation. Pediatr Transplant 2019;23:e13385.Google Scholar

Altassan, R., Witters, P., Saifudeen, Z., Quelhas, D., Jaeken, J., Levtchenko, E., et al. Renal involvement in PMM2-CDG, a mini-review. Mol Genet Metab 2018;123:292–6.CrossRef Google Scholar PubMed

Liapis, H.. Molecular pathology of nephrotic syndrome in childhood: a contemporary approach to diagnosis. Pediatr Dev Pathol 2008;11:154–63.Google Scholar

Gbadegesin, R., Hinkes, B. G., Hoskins, B. E., Vlangos, C. N., Heeringa, S. F., Liu, J., et al. Mutations in PLCE1 are a major cause of isolated diffuse mesangial sclerosis (IDMS). Nephrol Dial Transplant 2008;23:1291–7.Google Scholar

Kemper, M. J., Lemke, A.. Treatment of genetic forms of nephrotic syndrome. Front Pediatr 2018;6:72.Google Scholar

Nagatani, K., Hayashi, M.. Combination therapy improves pathology indices in diffuse mesangial sclerosis. Pediatr Int 2019;61:517–20.CrossRef Google Scholar PubMed

Sajantila, A., Salem, A. H., Savolainen, P., Bauer, K., Gierig, C., Paabo, S.. Paternal and maternal DNA lineages reveal a bottleneck in the founding of the Finnish population. Proc Natl Acad Sci U S A 1996;93:12035–9.Google Scholar

Hinkes, B. G., Mucha, B., Vlangos, C. N. et al.; Arbeitsgemeinschaft für Paediatrische Nephrologie Study Group. Nephrotic syndrome in the first year of life: Two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics 2007;119(4):e907–19.Google Scholar

Caridi, G., Bertelli, R., Di Duca, M., Dagnino, M., Emma, F., Onetti Muda, A., et al. Broadening the spectrum of diseases related to podocin mutations. J Am Soc Nephrol 2003;14:1278–86.Google Scholar

Boute, N., Gribouval, O., Roselli, S., Benessy, F., Lee, H., Fuchshuber, A., et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000;24:349–54.Google Scholar

Bierzynska, A., McCarthy, H. J., Soderquest, K., Sen, E. S., Colby, E., Ding, W. Y., et al. Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management. Kidney Int 2017;91:937–47.Google Scholar

Lovric, S., Ashraf, S., Tan, W., Hildebrandt, F.. Genetic testing in steroid-resistant nephrotic syndrome: when and how? Nephrol Dial Transplant 2016;31:1802–13.CrossRef Google Scholar PubMed

Ovunc, B., Ashraf, S., Vega-Warner, V., Bockenhauer, D., Elshakhs, N. A., Joseph, M., et al. Mutation analysis of NPHS1 in a worldwide cohort of congenital nephrotic syndrome patients. Nephron Clin Pract 2012;120:c139–46.Google Scholar

Romppanen, E. L., Mononen, I.. Detection of the Finnish-type congenital nephrotic syndrome by restriction fragment length polymorphism and dual-color oligonucleotide ligation assays. Clin Chem 2000;46:811–16.CrossRef Google Scholar PubMed

Patrakka, J., Kestila, M., Wartiovaara, J., Ruotsalainen, V., Tissari, P., Lenkkeri, U., et al. Congenital nephrotic syndrome (NPHS1): Features resulting from different mutations in Finnish patients. Kidney Int 2000;58:972–80.Google Scholar

Zhuo, L., Huang, L., Yang, Z., Li, G., Wang, L.. A comprehensive analysis of NPHS1 gene mutations in patients with sporadic focal segmental glomerulosclerosis. BMC Med Genet 2019;20:111.CrossRef Google Scholar PubMed

Roselli, S., Gribouval, O., Boute, N., Sich, M., Benessy, F., Attie, T., et al. Podocin localizes in the kidney to the slit diaphragm area. Am J Pathol 2002;160:131–19.CrossRef Google Scholar

Huber, T. B., Kottgen, M., Schilling, B., Walz, G., Benzing, T.. Interaction with podocin facilitates nephrin signaling. J Biol Chem 2001;276:41543–6.CrossRef Google Scholar PubMed

Sen, E. S., Dean, P., Yarram-Smith, L., Bierzynska, A., Woodward, G., Buxton, C., et al. Clinical genetic testing using a custom-designed steroid-resistant nephrotic syndrome gene panel: analysis and recommendations. J Med Genet 2017;54:795–804.CrossRef Google Scholar PubMed

Tory, K., Menyhard, D. K., Woerner, S., Nevo, F., Gribouval, O., Kerti, A., et al. Mutation-dependent recessive inheritance of NPHS2-associated steroid-resistant nephrotic syndrome. Nat Genet 2014;46:299–304.Google Scholar

Frishberg, Y., Rinat, C., Megged, O., Shapira, E., Feinstein, S., Raas-Rothschild, A.. Mutations in NPHS2 encoding podocin are a prevalent cause of steroid-resistant nephrotic syndrome among Israeli-Arab children. J Am Soc Nephrol 2002;13:400–5.CrossRef Google Scholar PubMed

Rood, I. M., Deegens, J. K. J., Lugtenberg, D., Bongers, E., Wetzels, J. F. M.. Nephrotic syndrome with mutations in NPHS2: The role of R229Q and implications for genetic counseling. Am J Kidney Dis 2019;73:400–3.CrossRef Google Scholar PubMed

Holmberg, C., Jalanko, H.. Congenital nephrotic syndrome and recurrence of proteinuria after renal transplantation. Pediatr Nephrol 2014;29:2309–17.Google Scholar

Wang, S. X., Ahola, H., Palmen, T., Solin, M. L., Luimula, P., Holthofer, H.. Recurrence of nephrotic syndrome after transplantation in CNF is due to autoantibodies to nephrin. Exp Nephrol 2001;9:327–31.Google Scholar

Becker-Cohen, R., Bruschi, M., Rinat, C., Feinstein, S., Zennaro, C., Ghiggeri, G. M., et al. Recurrent nephrotic syndrome in homozygous truncating NPHS2 mutation is not due to anti-podocin antibodies. Am J Transplant 2007;7:256–60.Google Scholar

Billing, H., Muller, D., Ruf, R., Lichtenberger, A., Hildebrandt, F., August, C., et al. NPHS2 mutation associated with recurrence of proteinuria after transplantation. Pediatr Nephrol 2004;19:561–4.CrossRef Google Scholar PubMed

Warejko, J. K., Tan, W., Daga, A., Schapiro, D., Lawson, J. A., Shril, S., et al. Whole exome sequencing of patients with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2018;13:53–62.Google Scholar

Varner, J. D., Chryst-Stangl, M., Esezobor, C. I., Solarin, A., Wu, G., Lane, B., et al. Genetic testing for steroid-resistant-nephrotic syndrome in an outbred population. Front Pediatr 2018;6:307.Google Scholar

Gulati, A., Sharma, A., Hari, P., Dinda, A. K., Bagga, A.. Idiopathic collapsing glomerulopathy in children. Clin Exp Nephrol 2008;12:348–53.Google Scholar

Haas, M.. Collapsing glomerulopathy: Many means to a similar end. Kidney Int 2008;73:669–71.Google Scholar

Chandra, P., Kopp, J. B.. Viruses and collapsing glomerulopathy: A brief critical review. Clin Kidney J 2013;6:1–5.CrossRef Google Scholar PubMed

Salvatore, S. P., Barisoni, L. M., Herzenberg, A. M., Chander, P. N., Nickeleit, V., Seshan, S. V.. Collapsing glomerulopathy in 19 patients with systemic lupus erythematosus or lupus-like disease. Clin J Am Soc Nephrol 2012;7:914–25.CrossRef Google Scholar PubMed

Markowitz, G. S., Nasr, S. H., Stokes, M. B., D’Agati, V. D.. Treatment with IFN-α, -β, or -γ is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010;5:607–15.Google Scholar

ten Dam, M. A., Hilbrands, L. B., Wetzels, J. F.. Nephrotic syndrome induced by pamidronate. Med Oncol 2011;28:1196–200.Google Scholar

Herlitz, L. C., Markowitz, G. S., Farris, A. B., Schwimmer, J. A., Stokes, M. B., Kunis, C., et al. Development of focal segmental glomerulosclerosis after anabolic steroid abuse. J Am Soc Nephrol 2010;21:163–72.CrossRef Google Scholar PubMed

Abid, Q., Best Rocha, A., Larsen, C. P., Schulert, G., Marsh, R., Yasin, S., et al. APOL1-associated collapsing focal segmental glomerulosclerosis in a patient with stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI). Am J Kidney Dis 2020;75:287–90.CrossRef Google Scholar

Swaminathan, S., Lager, D. J., Qian, X., Stegall, M. D., Larson, T. S., Griffin, M. D.. Collapsing and non-collapsing focal segmental glomerulosclerosis in kidney transplants. Nephrol Dial Transplant 2006;21:2607–14.Google Scholar

Ray, P. E., Li, J., Das, J. R., Tang, P.. Childhood HIV-associated nephropathy: 36 years later. Pediatr Nephrol 2021;36:2189–201.Google Scholar

Velez, J. C. Q., Caza, T., Larsen, C. P.. COVAN is the new HIVAN: The re-emergence of collapsing glomerulopathy with COVID-19. Nat Rev Nephrol 2020;16:565–7.Google Scholar

Genovese, G., Friedman, D. J., Ross, M. D., Lecordier, L., Uzureau, P., Freedman, B. I., et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010;329:841–5.Google Scholar

Limou, S., Nelson, G. W., Kopp, J. B., Winkler, C. A.. APOL1 kidney risk alleles: Population genetics and disease associations. Adv Chronic Kidney Dis 2014;21:426–33.Google Scholar

Friedman, D. J., Pollak, M. R.. APOL1 nephropathy: From genetics to clinical applications. Clin J Am Soc Nephrol 2021;16:294–303.Google Scholar

Sethna, C. B., Gipson, D. S.. Treatment of FSGS in children. Adv Chronic Kidney Dis 2014;21:194–9.Google Scholar

El-Refaey, A. M., Kapur, G., Jain, A., Hidalgo, G., Imam, A., Valentini, R. P., et al. Idiopathic collapsing focal segmental glomerulosclerosis in pediatric patients. Pediatr Nephrol 2007;22:396–402.CrossRef Google Scholar PubMed

Valeri, A., Barisoni, L., Appel, G. B., Seigle, R., D’Agati, V.. Idiopathic collapsing focal segmental glomerulosclerosis: A clinicopathologic study. Kidney Int 1996;50:1734–46.Google Scholar

Fiorentino, F., Napoletano, S., Caiazzo, F., Sessa, M., Bono, S., Spizzichino, L., et al. Chromosomal microarray analysis as a first-line test in pregnancies with a priori low risk for the detection of submicroscopic chromosomal abnormalities. Eur J Hum Genet 2013;21:725–30.Google Scholar

Verbitsky, M., Westland, R., Perez, A., Kiryluk, K., Liu, Q., Krithivasan, P., et al. The copy number variation landscape of congenital anomalies of the kidney and urinary tract. Nat Genet 2019;51:117–27.Google Scholar

Li, S., Han, X., Wang, Y., Chen, S., Niu, J., Qian, Z., et al. Chromosomal microarray analysis in fetuses with congenital anomalies of the kidney and urinary tract: A prospective cohort study and meta-analysis. Prenat Diagn 2019;39:165–74.Google Scholar

Tayeh, M. K., Chin, E. L., Miller, V. R., Bean, L. J., Coffee, B., Hegde, M.. Targeted comparative genomic hybridization array for the detection of single- and multiexon gene deletions and duplications. Genet Med 2009;11:232–40.Google Scholar

Zheng, M., Tian, S. Z., Capurso, D., Kim, M., Maurya, R., Lee, B., et al. Multiplex chromatin interactions with single-molecule precision. Nature 2019;566:558–62.Google Scholar

Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405–24.Google Scholar

Kaplan, J. M., Kim, S. H., North, K. N., Rennke, H., Correia, L. A., Tong, H. Q., et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 2000;24:251–6.Google Scholar

Bartram, M. P., Habbig, S., Pahmeyer, C., Hohne, M., Weber, L. T., Thiele, H., et al. Three-layered proteomic characterization of a novel ACTN4 mutation unravels its pathogenic potential in FSGS. Hum Mol Genet 2016;25:1152–64.CrossRef Google Scholar PubMed

Oegema, K., Savoian, M. S., Mitchison, T. J., Field, C. M.. Functional analysis of a human homologue of the Drosophila actin binding protein anillin suggests a role in cytokinesis. J Cell Biol 2000;150:539–52.Google Scholar

Gbadegesin, R. A., Hall, G., Adeyemo, A., Hanke, N., Tossidou, I., Burchette, J., et al. Mutations in the gene that encodes the F-actin binding protein anillin cause FSGS. J Am Soc Nephrol 2014;25:1991–2002.CrossRef Google Scholar PubMed

Akilesh, S., Suleiman, H., Yu, H., Stander, M. C., Lavin, P., Gbadegesin, R., et al. Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis. J Clin Invest 2011;121:4127–37.Google Scholar

Gigante, M., Pontrelli, P., Montemurno, E., Roca, L., Aucella, F., Penza, R., et al. CD2AP mutations are associated with sporadic nephrotic syndrome and focal segmental glomerulosclerosis (FSGS). Nephrol Dial Transplant 2009;24:1858–64.Google Scholar

Takano, T., Bareke, E., Takeda, N., Aoudjit, L., Baldwin, C., Pisano, P., et al. Recessive mutation in CD2AP causes focal segmental glomerulosclerosis in humans and mice. Kidney Int 2019;95:57–61.Google Scholar

Lowik, M. M., Groenen, P. J., Pronk, I., Lilien, M. R., Goldschmeding, R., Dijkman, H. B., et al. Focal segmental glomerulosclerosis in a patient homozygous for a CD2AP mutation. Kidney Int 2007;72:1198–203.Google Scholar

Boyer, O., Nevo, F., Plaisier, E., Funalot, B., Gribouval, O., Benoit, G., et al. INF2 mutations in Charcot-Marie-Tooth disease with glomerulopathy. N Engl J Med 2011;365:2377–88.Google Scholar

Dong, F., Li, S., Pujol-Moix, N., Luban, N. L., Shin, S. W., Seo, J. H., et al. Genotype-phenotype correlation in MYH9-related thrombocytopenia. Br J Haematol 2005;130:620–7.Google Scholar

Tabibzadeh, N., Fleury, D., Labatut, D., Bridoux, F., Lionet, A., Jourde-Chiche, N., et al. MYH9-related disorders display heterogeneous kidney involvement and outcome. Clin Kidney J 2019;12:494–502.Google Scholar

Hall, G., Wang, L., Spurney, R. F.. TRPC channels in proteinuric kidney diseases. Cells 2019;9: 44.Google Scholar

Winn, M. P., Conlon, P. J., Lynn, K. L., Farrington, M. K., Creazzo, T., Hawkins, A. F., et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005;308:1801–4.Google Scholar

Reiser, J., Polu, K. R., Moller, C. C., Kenlan, P., Altintas, M. M., Wei, C., et al. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet 2005;37:739–44.Google Scholar

Xiong, S., Shuai, L., Li, X., Dang, X., Wu, X., He, Q.. Podocytic infolding in Schimke immuno-osseous dysplasia with novel SMARCAL1 mutations: A case report. BMC Nephrol 2020;21:170.Google Scholar

Okumura, T., Furuichi, K., Higashide, T., Sakurai, M., Hashimoto, S., Shinozaki, Y., et al. Association of PAX2 and other gene mutations with the clinical manifestations of renal coloboma syndrome. PLoS ONE 2015;10:e0142843.Google Scholar

Vivante, A., Chacham, O. S., Shril, S., Schreiber, R., Mane, S. M., Pode-Shakked, B., et al. Dominant PAX2 mutations may cause steroid-resistant nephrotic syndrome and FSGS in children. Pediatr Nephrol 2019;34:1607–13.CrossRef Google Scholar PubMed

Stefanidis, C. J., Querfeld, U.. The podocyte as a target: Cyclosporin A in the management of the nephrotic syndrome caused by WT1 mutations. Eur J Pediatr 2011;170:1377–83.CrossRef Google Scholar PubMed

Barbaux, S., Niaudet, P., Gubler, M. C., Grunfeld, J. P., Jaubert, F., Kuttenn, F., et al. Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat Genet 1997;17:467–70.Google Scholar

Denamur, E., Bocquet, N., Mougenot, B., Da Silva, F., Martinat, L., Loirat, C., et al. Mother-to-child transmitted WT1 splice-site mutation is responsible for distinct glomerular diseases. J Am Soc Nephrol 1999;10:2219–23.Google Scholar

Demmer, L., Primack, W., Loik, V., Brown, R., Therville, N., McElreavey, K.. Frasier syndrome: A cause of focal segmental glomerulosclerosis in a 46,XX female. J Am Soc Nephrol 1999;10:2215–18.Google Scholar

Gee, H. Y., Saisawat, P., Ashraf, S., Hurd, T. W., Vega-Warner, V., Fang, H., et al. ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling. J Clin Invest 2013;123:3243–53.Google Scholar

Korkmaz, E., Lipska-Zietkiewicz, B. S., Boyer, O., Gribouval, O., Fourrage, C., Tabatabaei, M., et al. ADCK4-associated glomerulopathy causes adolescence-onset FSGS. J Am Soc Nephrol 2016;27:63–8.Google Scholar

Rao, J., Ashraf, S., Tan, W., van der Ven, A. T., Gee, H. Y., Braun, D. A., et al. Advillin acts upstream of phospholipase C 1 in steroid-resistant nephrotic syndrome. J Clin Invest 2017;127:4257–69.Google Scholar

Ebarasi, L., Ashraf, S., Bierzynska, A., Gee, H. Y., McCarthy, H. J., Lovric, S., et al. Defects of CRB2 cause steroid-resistant nephrotic syndrome. Am J Hum Genet 2015;96:153–61.Google Scholar

Slavotinek, A., Kaylor, J., Pierce, H., Cahr, M., DeWard, S. J., Schneidman-Duhovny, D., et al. CRB2 mutations produce a phenotype resembling congenital nephrosis, Finnish type, with cerebral ventriculomegaly and raised alpha-fetoprotein. Am J Hum Genet 2015;96:162–9.Google Scholar

Gee, H. Y., Sadowski, C. E., Aggarwal, P. K., Porath, J. D., Yakulov, T. A., Schueler, M., et al. FAT1 mutations cause a glomerulotubular nephropathy. Nat Commun 2016;7:10822.Google Scholar

Gee, H. Y., Zhang, F., Ashraf, S., Kohl, S., Sadowski, C. E., Vega-Warner, V., et al. KANK deficiency leads to podocyte dysfunction and nephrotic syndrome. J Clin Invest 2015;125:2375–84.Google Scholar

Balbas, M. D., Burgess, M. R., Murali, R., Wongvipat, J., Skaggs, B. J., Mundel, P., et al. MAGI-2 scaffold protein is critical for kidney barrier function. Proc Natl Acad Sci U S A 2014;111:14876–81.Google Scholar

Bierzynska, A., Soderquest, K., Dean, P., Colby, E., Rollason, R., Jones, C., et al. MAGI2 mutations cause congenital nephrotic syndrome. J Am Soc Nephrol 2017;28:1614–21.Google Scholar

Mele, C., Iatropoulos, P., Donadelli, R., Calabria, A., Maranta, R., Cassis, P., et al. MYO1E mutations and childhood familial focal segmental glomerulosclerosis. N Engl J Med 2011;365:295–306.Google Scholar

Hashmi, J. A., Safar, R. A., Afzal, S., Albalawi, A. M., Abdu-Samad, F., Iqbal, Z., et al. Whole exome sequencing identification of a novel insertion mutation in the phospholipase C epsilon1 gene in a family with steroid resistant inherited nephrotic syndrome. Mol Med Rep 2018;18:5095–100.Google Scholar

Tasic, V., Gucev, Z., Polenakovic, M.. Steroid resistant nephrotic syndrome-genetic consideration. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2015;36:5–12.Google Scholar

Ozaltin, F., Ibsirlioglu, T., Taskiran, E. Z., Baydar, D. E., Kaymaz, F., Buyukcelik, M., et al. Disruption of PTPRO causes childhood-onset nephrotic syndrome. Am J Hum Genet 2011;89:139–47.Google Scholar

Ashraf, S., Gee, H. Y., Woerner, S., Xie, L. X., Vega-Warner, V., Lovric, S., et al. ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. J Clin Invest 2013;123:5179–89.Google Scholar

Quinzii, C., Naini, A., Salviati, L., Trevisson, E., Navas, P., Dimauro, S., et al. A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am J Hum Genet 2006;78:345–9.Google Scholar

Lopez, L. C., Schuelke, M., Quinzii, C. M., Kanki, T., Rodenburg, R. J., Naini, A., et al. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet 2006;79:1125–9.CrossRef Google Scholar PubMed

Hermle, T., Schneider, R., Schapiro, D., Braun, D. A., van der Ven, A. T., Warejko, J. K., et al. GAPVD1 and ANKFY1 mutations implicate RAB5 regulation in nephrotic syndrome. J Am Soc Nephrol 2018;29:2123–38.Google Scholar

Wan, X., Chen, Z., Choi, W. I., Gee, H. Y., Hildebrandt, F., Zhou, W.. Loss of epithelial membrane protein 2 aggravates podocyte injury via upregulation of caveolin-1. J Am Soc Nephrol 2016;27:1066–75.Google Scholar

Gee, H. Y., Ashraf, S., Wan, X., Vega-Warner, V., Esteve-Rudd, J., Lovric, S., et al. Mutations in EMP2 cause childhood-onset nephrotic syndrome. Am J Hum Genet 2014;94:884–90.Google Scholar

van Berkel, Y., Ludwig, M., van Wijk, J. A. E., Bokenkamp, A.. Proteinuria in Dent disease: A review of the literature. Pediatr Nephrol 2017;32:1851–9.Google Scholar

Dorval, G., Kuzmuk, V., Gribouval, O., Welsh, G. I., Bierzynska, A., Schmitt, A., et al. TBC1D8B loss-of-function mutations lead to X-linked nephrotic syndrome via defective trafficking pathways. Am J Hum Genet 2019;104:348–55.Google Scholar

Sanna-Cherchi, S., Burgess, K. E., Nees, S. N., Caridi, G., Weng, P. L., Dagnino, M., et al. Exome sequencing identified MYO1E and NEIL1 as candidate genes for human autosomal recessive steroid-resistant nephrotic syndrome. Kidney Int 2011;80:389–96.Google Scholar

Has, C., Sparta, G., Kiritsi, D., Weibel, L., Moeller, A., Vega-Warner, V., et al. Integrin alpha3 mutations with kidney, lung, and skin disease. N Engl J Med 2012;366:1508–14.Google Scholar

Kambham, N., Tanji, N., Seigle, R. L., Markowitz, G. S., Pulkkinen, L., Uitto, J., et al. Congenital focal segmental glomerulosclerosis associated with beta4 integrin mutation and epidermolysis bullosa. Am J Kidney Dis 2000;36:190–6.Google Scholar

Berkovic, S. F., Dibbens, L. M., Oshlack, A., Silver, J. D., Katerelos, M., Vears, D. F., et al. Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis. Am J Hum Genet 2008;82:673–84.Google Scholar

Prasad, R., Hadjidemetriou, I., Maharaj, A., Meimaridou, E., Buonocore, F., Saleem, M., et al. Sphingosine-1-phosphate lyase mutations cause primary adrenal insufficiency and steroid-resistant nephrotic syndrome. J Clin Invest 2017;127:942–53.Google Scholar

Davis, E. E., Zhang, Q., Liu, Q., Diplas, B. H., Davey, L. M., Hartley, J., et al. TTC21B contributes both causal and modifying alleles across the ciliopathy spectrum. Nat Genet 2011;43:189–96.Google Scholar PubMed

Bullich, G., Vargas, I., Trujillano, D., Mendizabal, S., Pinero-Fernandez, J. A., Fraga, G., et al. Contribution of the TTC21B gene to glomerular and cystic kidney diseases. Nephrol Dial Transplant 2017;32:151–6.Google Scholar

Huynh Cong, E., Bizet, A. A., Boyer, O., Woerner, S., Gribouval, O., Filhol, E., et al. A homozygous missense mutation in the ciliary gene TTC21B causes familial FSGS. J Am Soc Nephrol 2014;25:2435–43.Google Scholar

Braun, D. A., Rao, J., Mollet, G., Schapiro, D., Daugeron, M. C., Tan, W., et al. Mutations in KEOPS-complex genes cause nephrotic syndrome with primary microcephaly. Nat Genet 2017;49:1529–38.Google Scholar

Shaheen, R., Abdel-Salam, G. M., Guy, M. P., Alomar, R., Abdel-Hamid, M. S., Afifi, H. H., et al. Mutation in WDR4 impairs tRNA m(7)G46 methylation and causes a distinct form of microcephalic primordial dwarfism. Genome Biol 2015;16:210.Google Scholar

Rosti, R. O., Sotak, B. N., Bielas, S. L., Bhat, G., Silhavy, J. L., Aslanger, A. D., et al. Homozygous mutation in NUP107 leads to microcephaly with steroid-resistant nephrotic condition similar to Galloway-Mowat syndrome. J Med Genet 2017;54:399–403.Google Scholar

Fujita, A., Tsukaguchi, H., Koshimizu, E., Nakazato, H., Itoh, K., Kuraoka, S., et al. Homozygous splicing mutation in NUP133 causes Galloway-Mowat syndrome. Ann Neurol 2018;84:814–28.Google Scholar

Jinks, R. N., Puffenberger, E. G., Baple, E., Harding, B., Crino, P., Fogo, A. B., et al. Recessive nephrocerebellar syndrome on the Galloway-Mowat syndrome spectrum is caused by homozygous protein-truncating mutations of WDR73. Brain 2015;138:2173–90.Google Scholar

Braun, D. A., Sadowski, C. E., Kohl, S., Lovric, S., Astrinidis, S. A., Pabst, W. L., et al. Mutations in nuclear pore genes NUP93, NUP205 and XPO5 cause steroid-resistant nephrotic syndrome. Nat Genet 2016;48:457–65.Google Scholar

Braun, D. A., Lovric, S., Schapiro, D., Schneider, R., Marquez, J., Asif, M., et al. Mutations in multiple components of the nuclear pore complex cause nephrotic syndrome. J Clin Invest 2018;128:4313–28.Google Scholar

Watts, A. J. B., Keller, K. H, Lerner, G., Rosales, I., Collins, A.B., Sekulic, M., et al. Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J Am Soc Nephrol 2022;33:238–52.Google Scholar

References

Funk, S. D., Lin, M.-H., Miner, J. H.. Alport syndrome and Pierson syndrome: diseases of the glomerular basement membrane. Matrix Biol 2018; 71–72: 250–61.Google Scholar

Harvey, S. J., Jarad, G., Cunningham, J. et al. Disruption of glomerular basement membrane charge through podocyte-specific mutation of agrin does not alter glomerular perm selectivity. Am J Pathol 2007; 171: 139–52.CrossRef Google Scholar PubMed

Muller-Diele, J., Dannenberg, J., Schroder, P. et al. Podocytes regulate the glomerular basement membrane protein nephronectin by means of miR-378a-3p in glomerular diseases. Kidney Int 2017; 92: 836–49.Google Scholar

Zimmermann, S. E., Hiremath, C., Tsunezumi, J. et al. Nephronectin regulates mesangial cell adhesion and behaviour in glomeruli. J Am Soc Nephrol 2018; 29: 1128–40.Google Scholar

Brown, K. L., Cummings, C. F., Vanacore, R. M., Hudson, B. G.. Building collagen IV smart scaffolds on the outside of cells. Protein Sci 2017; 26: 2151–61.Google Scholar

Abrahamson, D. R., Hudson, B. G., Sroganova, L., Borza, D.-B., St John, P. L.. Cellular origins of type IV collagen networks in developing glomeruli. J Am Soc Nephrol 2009; 20: 1471–79.Google Scholar

Matthaiou, A., Poulli, T., Deltas, C.. Prevalence of clinical, pathological and molecular features of glomerular basement membrane nephropathy caused by COL4A3 or Col4A4 mutations: a systematic review. Clin Kidney J 2020; 13: 1025–36.Google Scholar

Kashtan, C. E., Ding, J., Garosi, G. et al. Alport syndrome: a unified classification of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group. Kidney Int 2018; 93: 1045–51.Google Scholar

Jais, J. P., Knebelmann, B., Giatris, I. et al. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: A ‘European Community Alport Syndrome Concerted Action’ study. J Am Soc Nephrol 2003; 14: 2603–10.Google Scholar

Malone, A. F., Phelan, P. J., Hall, G. et al. Rare hereditary COL4A3/COL4A4 variants may be mistaken for familial focal segmental glomerulosclerosis. Kidney Int 2014; 86: 1253–59.Google Scholar

Savige, J., Storey, H., Watson, E. et al. Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria. Eur J Hum Genet 2021; 29: 1186–97.Google Scholar

Jais, J. P., Knebelmann, B., Giatris, I. et al. X-linked Alport syndrome: natural history in 195 families and genotype-phenotype correlations in males. J Am Soc Nephrol 2000; 11: 649–57.Google Scholar

Yamamura, T., Horinouchi, T., Nagano, C. et al. Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome. Kidney Int 2020; 98: 1605–14.Google Scholar

Nozu, K., Nakanishi, K., Abe, Y. et al. A review of clinical characteristics and genetic backgrounds in Alport syndrome. Clin Exp Nephrol 2019; 23: 158–68.Google Scholar

Gross, O., Netzer, K. O., Lambrecht, R., Seibold, S., Weber, M.. Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling. Nephrol Dial Transplant 2002; 17: 1218–27.Google Scholar

Savige, J., Sheth, S., Leys, A. et al. Ocular features in Alport syndrome: pathogenesis and clinical significance. Clin J Am Soc Nephrol 2015; 10: 703–9.Google Scholar

Lee, J. M., Nozu, K., Choi, D. E. et al. Features of autosomal recessive Alport syndrome: a systematic review. J Clin Med 2019; 8: 178.Google Scholar

Furlano, M., Martinez, V., Pybus, M. et al. Clinical and genetic features of autosomal dominant Alport syndrome: a cohort series. Am J Kidney Dis 2021; 78: 560–70.Google Scholar

Randels, M., Collinson, S., Starborg, T. et al. Three-dimensional electron microscopy reveals the evolution of glomerular barrier injury. Sci Rep 2016; 6: 35068.Google Scholar

Wickman, L., Hodgin, J. B., Wang, S. Q. et al. Podocyte depletion in thin GBM and Alport syndrome. PLoS ONE 2018; 11: e0155255.Google Scholar

Savige, J., Ariani, F., Mari, F. et al. Expert consensus guidelines for the genetic diagnosis of Alport syndrome. Ped Nephrol 2019; 34: 1175–89.Google Scholar

Torra, R., Furlano, M., Ars, E.. How genomics reclassifies diseases: the case of Alport syndrome. Clin Kidney J 2020; 13: 933–35.Google Scholar

Gross, O., Beirowski, B., Koepke, M. L. et al. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 2003; 63: 438–46.Google Scholar

Gross, O., Licht, C., Anders, H. J. et al. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 2012; 81: 494–501.Google Scholar

Gross, O., Tonshoff, B., Weber, L. T. et al. GPN study group and EARLY PRO-TECT Alport Investigators: a multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndrome. Kidney Int 2020; 97: 1275–86.Google Scholar

Kashtan, C. E., Gross, O.. Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020. Published correction appears in Pediatr Nephrol 2021; 36: 731.Google Scholar

Torra, R., Furlano, M.. New therapeutic options for Alport syndrome. Nephrol Dial Transplant 2019; 34: 1272–9.Google Scholar

Quinlan, C., Rheault, M. N.. Genetic basis of type IV collagen disorders of the kidney. CJASN 2021; CJN.19171220.Google Scholar

Savige, J., Rana, K., Tonna, S. et al. Thin basement membrane nephropathy. Kidney Int 2003; 64: 1169–78.Google Scholar

Wang, Y. Y., Rana, K., Tonna, S., Lin, T., Sin, L., Savige, J.. COL4A3 mutations and their clinical consequences in thin basement membrane nephropathy (TBMN). Kidney Int 2004; 65: 786–90.Google Scholar

Savige, J.. A further genetic cause of thin basement membrane nephropathy. Nephrol Dial Transplant 2016; 31: 1758–60.Google Scholar

Tryggvasan, K., Patrakka, J.. Thin basement membrane nephropathy. J Am Soc Nephrol 2006; 17: 813–22.Google Scholar

Haas, M.. Alport syndrome and thin glomerular basement membrane nephropathy. A practical approach to diagnosis. Arch Pathol Lab Med 2009; 133: 2224–32.Google Scholar

Lemmink, H. H., Nillesen, W. N., Mochizuki, T. et al. Benign familial haematuria due to mutation of the type IV collagen α4 gene. J Clin Invest 1996; 9: 1114–18.Google Scholar

Frasca, G. M., Onetti-Muda, A., Mari, F. et al. Thin glomerular basement membrane disease: clinical significance of a morphological diagnosis-a collaborative study of the Italian Renal Immunopathology Group. Nephrol Dial Transplant 2005; 20: 545–51.Google Scholar

Thomas, D. M., Coles, G. A., Griffiths, D. F., Williams, J. D.. Perm selectivity in thin basement membrane nephropathy. J Clin Invest 1994; 93: 1881–4.Google Scholar

Berthoux, F. C., Laurent, B., Alamartine, E., Diab, N.. New subgroup of primary IgA nephritis with thin glomerular basement membrane (GBM): syndrome or association. Nephrol Dial Transplant 1996; 11: 558–9.Google Scholar

Taguchi, T., von Bassewitz, D. B., Grundmann, E., Takebayashi, S.. Ultrastructural changes of glomerular basement membrane in IgA nephritis: relationship to hematuria. Ultrastruct Pathol 1988; 12: 17–26.Google Scholar

Das, A. K., Pickett, T. M., Tungekar, M. F.. Glomerular basement membrane thickness-a comparison of two methods of measurement in patients with unexplained hematuria. Nephrol Dial Transplant 1996; 11: 1256–60.Google Scholar

Dische, F. E.. Measurement of glomerular basement membrane thickness and its application to the diagnosis of thin-membrane nephropathy. Arch Pathol Lab Med 1992; 116: 43–9.Google Scholar

Tiebosch, A. T. M. G., Frederik, P. M., van Breda Vriesman, P. J. C. et al. Thin-basement-membrane nephropathy in adults with persistent hematuria. N Eng J Med 1989; 320: 14–18.Google Scholar

Foster, K., Markowitz, G. S., D’Agati, V. D.. Pathology of thin basement membrane nephropathy. Semin Nephrol 2005; 25: 149–58.Google Scholar

Vogler, C., McAdam, A. J., Homan, S. M.. Glomerular basement membrane and lamina densa in infants and children: an ultrastructural evaluation. Pediatr Pathol 1987; 7: 527–34.Google Scholar

Collar, J. E., Ladva, S., Cairns, T. D. H., Cattell, V.. Red cell traverse through thin glomerular basement membranes. Kidney Int 2001; 59: 2069–72.Google Scholar

Deltas, C., Pierides, A., Voskarides, K.. The role of molecular genetics in diagnosing familial hematuria(s). Pediatr Nephrol 2012; 27: 1221–31.Google Scholar

Pierides, A., Voskarides, K., Kkolou, M., Hadjigavriel, M., Deltas, C.. X-linked, COL4A5 hypomorphic Alport mutations such as G624D and P628L may only exhibit thin basement membrane nephropathy with microhematuria and late onset kidney failure. Hippokatia 2013; 17: 207–13.Google Scholar

Koskarides, K., Demosthenous, P., Papazachariou, L. et al. Epistatic role of the MYH9/APOL1 region on familial hematuria genes. PLoS ONE 2013; 8(3): e57925.Google Scholar

Gale, D., Deren Oygar, D., Lin F, F. et al. A novel COL4A1 frameshift mutation in familial kidney disease: the importance of the C-terminal NC1 domain of type IV collagen. Nephrol Dial Transplant 2016; 31: 1908–14.Google Scholar

Ghoumid, J., Petit, F., Holder-Espinasse, M. et al. Nail-patella syndrome: clinical and molecular data in 55 families missing the hypothesis of a genetic heterogeneity. Eur J Hum Genet 2016; 24: 44–50.Google Scholar

Boyer, O., Woerner, S., Yang, F. et al. LMX1B mutations cause hereditary FSGS without extrarenal involvement. J Am Soc Nephrol 2013; 24: 1216–22.Google Scholar

Harita, Y., Kitanaka, S., Isojima, T., Ashida, A., Hattori, M.. Spectrum of LMX1B mutations: from nail-patella syndrome to isolated nephropathy. Pediatr Nephrol 2017; 32: 1845–50.Google Scholar

Morello, R., Zhou, G., Dreyer, S. D. et al. Regulation of glomerular basement membrane collagen expression by LMX1B contributes to renal disease in nail patella syndrome. Nat Genet 2001; 27: 205–8.Google Scholar

Heidet, L., Bongers, E. M. H. F., Sich, M. et al. In vivo expression of putative LMX1B targets in nail-patella syndrome kidneys. Am J Pathol 2003; 163: 145–55.Google Scholar

Miner, J. H., Morello, R., Andrews, K. L. et al. Transcriptional induction of slit diaphragm genes by Lmx1b is required in podocyte differentiation. J Clin Invest 2002; 109: 1065–72.Google Scholar

Rohr, C., Prestel, J., Heidet, L. et al. The LIM-homeodomain transcription factor Lmx1b plays a crucial role in podocytes. J Clin Invest 2002; 109: 1073–82.Google Scholar

Bongers, E. M. H. F., Gubler, M. C., Knoers, N. V. A. M.. Nail-patella syndrome. Overview on clinical and molecular findings. Pediatr Nephrol 2002; 17: 703–12.Google Scholar

Lemley, K. V.. Kidney disease in nail-patella syndrome. Pediatr Nephrol 2009; 24: 2345–54.Google Scholar

Sweeney, E., Fryer, A., Mountford, R., Green, A., McIntoch, I.. Nail patella syndrome: a review of the phenotype aided by developmental biology. J Med Genet 2003; 40: 153–62.Google Scholar

Harita, Y., Urae, S., Akashio, R. et al. Clinical and genetic characterization of nephropathy in patients with nail-patella syndrome. Eur J Hum Genet 2020; 28: 1414–21.Google Scholar

Aboobacker, I. N., Krishnakumar, A., Narayanan, S. et al. Nail-patella syndrome: a rare cause of nephrotic syndrome in pregnancy. Indian J Nephrol 2018; 28: 76–8.Google Scholar

Konomoto, T., Imamura, H., Orita, M. et al. Clinical and histological findings of autosomal dominant renal-limited disease with LMX1B mutation. Nephrology 2016; 21: 765–73.Google Scholar

Pinto e Vairo, F., Pichurin, P. N., Fervenza, F. C. et al. Nail-patella-like renal disease masquerading as Fabry disease on kidney biopsy: a case report. BMC Nephrology 2020; 21: 341.Google Scholar

Zenker, M., Aigner, T., Wendler, O. et al. Human laminin β2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. Hum Mol Genet 2004; 13: 2625–32.Google Scholar

Chew, C., Lennon, R.. Basement membrane defects in genetic kidney diseases. Front Pediatr 2018; 6: 11.Google Scholar

Pierson, M., Cordier, J., Hervouuet, F., Rauber, G.. An unusual congenital and familial congenital malformative combination involving the eye and kidney. J Genet Hum 1963; 12: 184–213.Google Scholar

Nishiyama, K., Kurokawa, M., Torio, M. et al. Gastrointestinal symptoms as an extended clinical feature of Pierson syndrome: a case report and review of the literature. BMC Medical Genetics 2020; 21: 80.Google Scholar

Kulali, F., Calkavur, S., Basaran, C. et al. A new mutation associated with Pierson syndrome. Arch Argent Pediatr 2020; 118: e288–91.Google Scholar

Hasselbacher, K., Wiggins, R. C., Matejas, V. et al. Recessive missense mutations in LAMB2 expand the clinical spectrum of LAMB2-associated disorders. Kidney Int 2006; 70: 1008–12.Google Scholar

Sakuraya, K., Nozu, K., Murakami, H. et al. An extremely mild clinical course in a case with LAMB2-associated nephritis diagnosed with next-generation sequencing. CEN Case Rep 2021; 10: 359–63.Google Scholar

Kikkawa, Y., Hashimoto, T., Takizawa, K. et al. Laminin β2 variants associated with isolated nephropathy that impact matrix regulation. JCI Insight 2021; 22: e145908.Google Scholar

Zenker, M., Pierson, M., Jonveaux, P., Reis, A.. Demonstration of two novel LAMB2 mutations in the original Pierson syndrome family reported 42 years ago. Am J Med Genet A 2005; 138: 73–4.Google Scholar

Arakawa, M., Fueki, H., Hirano, H. et al. Idiopathic mesangio-degenerative glomerulopathy. Jpn J Nephrol 1979; 21: 914–15.Google Scholar

Imbasciati, E., Gherardi, G., Morozumi, K. et al. Collagen type III glomerulopathy: a new idiopathic glomerular disease. Am J Nephrol 1991; 11: 422–9.Google Scholar

Bao, H., Chen, H., Zhu, X. et al. Clinical and morphological features of collagen type III glomerulopathy: a report of nine cases from a single institution. Histopathology 2015; 67: 568–76.Google Scholar

Miyake, M., Katayama, K., Ehara, T. et al. Collagenofibrotic glomerulopathy. Intern Med 2021; 60: 911–15.Google Scholar

Rortveit, R., Lingaas, F., Bonsdorff, T. et al. A canine autosomal recessive model of collagen type III glomerulopathy. Lab Invest 2012; 92: 1483–91.Google Scholar

Duggal, R., Nada, R., Singh Rayat, C. et al. Collagenofibrotic glomerulopathy-a review. Clin Kidney J 2012; 5: 7–12.Google Scholar

Yasuda, T., Imai, H., Nakamoto, Y. et al. Collagenofibrotic glomerulopathy: a systemic disease. Am J Kidney Dis 1999; 33: 123–7.Google Scholar

Manocha, A., Gupta, P.. Collagenofibrotic glomerulopathy: a rare diagnosis and seldom thought of differential for nodular glomerular mesangial expansion. J Clin Diagn Res 2020; 14: ED01–ED02.Google Scholar

Mizuiri, S., Hasegawa, A., Kikuchi, A. et al. A case of collagenofibrotic glomerulopathy associated with hepatic perisinusoidal fibrosis. Nephron 1993; 63: 183–7.Google Scholar

Gubler, M. C., Dommergues, J. P., Foulard, M. et al. Collagen type III glomerulopathy: a new type of hereditary nephropathy. Pediatr Nephrol 1993; 7: 354–60.Google Scholar

Salcedo, J. R.. An autosomal recessive disorder with glomerular basement membrane abnormalities similar to those seen in nail patella syndrome: report of a kindred. Am J Med Genet 1984; 19: 579–84.Google Scholar

Aoki, T., Hayashi, K., Morinaga, T. et al. Two brothers with collagenofibrotic glomerulopathy. CEN Case Rep 2015; 4: 85–9.Google Scholar

Alsaad, K. O., Edrees, B., Rahim, K. A. et al. Collagenofibrotic (collagen type III) glomerulopathy in association with diabetic nephropathy. Saudi J Kidney Dis Transpl 2017; 28: 898–905.Google Scholar

Vogt, B. A., Wyatt, R. J., Burke, B. A. et al. Inherited factor H deficiency and collagen type III glomerulopathy. Pediatr Nephrol 1995; 9: 11–15.Google Scholar

Suzuki, T., Okubo, S., Ikezumii, Y. et al. Favourable course of collagenofibrotic glomerulopathy after kidney transplantation and questionnaire survey about the prognosis of collagenofibrotic glomerulopathy. Nihon Jinzo Gakkai Shi 2004; 46: 360–4.Google Scholar

Ferreira, R. D. R., Custodio, F. B., Guimaraes, C. S. O., Correa, R. R. M., Reis, M. A.. Collagenofibrotic glomerulopathy: three case reports in Brazil. Diagn Pathol 2009; 4: 33.Google Scholar

Fukami, K., Yamagishi, S., Minezaki, T. et al. First reported case of collagenofibrotic glomerulopathy with a full house pattern of immune deposits. Clin Nephrol 2014; 81: 290–5.Google Scholar

Guo, Q., Liu, L., Nie, P., Luo, P.. Telmisartan alleviated collagen type III glomerulopathy: a case report with literature review. Exp Ther Med 2020; 20: 140.Google Scholar

References

Noris, M., Remuzzi, G.. Genetics of immune-mediated glomerular diseases: Focus on complement. Semin Nephrol. 2017;37:447–63.Google Scholar

Couser, W. G.. Basic and translational concepts of immune-mediated glomerular diseases. J Am Soc Nephrol. 2012;23:381–99.Google Scholar

O’Shaughnessy, M. M., Hogan, S. L., Thompson, B. D., Coppo, R., Fogo, A. B., Jennette, J. C.. Glomerular disease frequencies by race, sex and region: Results from the International Kidney Biopsy Survey. Nephrol Dial Transplant. 2018;33:661–9.Google Scholar

Sugiyama, H., Yokoyama, H., Sato, H., et al. Japan Renal Biopsy Registry and Japan Kidney Disease Registry: Committee report for 2009 and 2010. Clin Exp Nephrol. 2013;17:155–73.Google Scholar

Cho, B. S., Hahn, W. H., Cheong, H. I., et al. A nationwide study of mass urine screening tests on Korean school children and implications for chronic kidney disease management. Clin Exp Nephrol. 2013;17:205–10.Google Scholar

Shibano, T., Takagi, N., Maekawa, K., Mae, H., Hattori, M., Takeshima, Y., Tanizawa, T.. Epidemiological survey and clinical investigation of pediatric IgA nephropathy. Clin Exp Nephrol. 2016;20:111–17.Google Scholar

Mizerska-Wasiak, M., Turczyn, A., Such, A., et al. IgA nephropathy in children: a multicenter study in Poland. Adv Exp Med Biol. 2016;952:75–84.Google Scholar

Coppo, R.. Pediatric IgA nephropathy in Europe. Kidney Dis (Basel). 2019;5:182–8.Google Scholar

Gharavi, A. G., Kiryluk, K., Choi, M., et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 2011;43:321–7.Google Scholar

Rheault, M. N., Wenderfer, S. E.. Evolving epidemiology of pediatric glomerular disease. Clin J Am Soc Nephrol. 2018;13:977–8.Google Scholar

Yeo, S. C., Cheung, C. K., Barratt, J.. New insights into the pathogenesis of IgA nephropathy. Pediatr Nephrol. 2018;33:763–77.Google Scholar

Park, H. J., Hahn, W. H., Suh, J. S., et al. Association between toll-like receptor 10 (TLR10) gene polymorphisms and childhood IgA nephropathy. Eur J Pediatr. 2011;170:503–9.Google Scholar

Donadio, M. E., Loiacono, E., Peruzzi, L., et al. Toll-like receptors, immunoproteasome and regulatory T cells in children with Henoch-Schönlein purpura and primary IgA nephropathy. Pediatr Nephrol. 2014;29:1545–51.Google Scholar

Coppo, R., Robert, T.. IgA nephropathy in children and in adults: Two separate entities or the same disease? J Nephrol. 2020;33:1219–29.Google Scholar

Coppo, R., Lofaro, D., Camilla, R. R., et al. Risk factors for progression in children and young adults with IgA nephropathy: An analysis of 261 cases from the VALIGA European cohort. Pediatr Nephrol. 2017;32:139–50. Erratum in: Pediatr Nephrol. 2017;32:193–94.Google Scholar

Espinosa, M., Ortega, R., Sánchez, M., et al. Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2014;9:897–904.Google Scholar

Fabiano, R. C. G., de Almeida, A. S., Bambirra, E. A., Oliveira, E. A., Silva, A. C. S. E., Pinheiro, S. V. B.. Mesangial C4d deposition may predict progression of kidney disease in pediatric patients with IgA nephropathy. Pediatr Nephrol. 2017;32:1211–20.Google Scholar

Suzuki, H., Ohsawa, I., Kodama, F., et al. Fluctuation of serum C3 levels reflects disease activity and metabolic background in patients with IgA nephropathy. J Nephrol. 2013;26:708–15.Google Scholar

Coppo, R.. Pediatric IgA nephropathy in Europe. Kidney Dis (Basel). 2019;5:182–8.Google Scholar

Mizerska-Wasiak, M., Maldyk, J., Panczyk-Tomaszewska, M., et al. Increased serum IgA in children with IgA nephropathy, severity of kidney biopsy findings and long-term outcomes. Adv Exp Med Biol. 2015;873:79–86.Google Scholar

Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts, I. S., Cook, H. T., et al. The Oxford classification of IgA nephropathy: Pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76:546–56.Google Scholar

Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran, D.C., Coppo, R., et al., The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76:534–45.Google Scholar

Rivera, F., López-Gómez, J. M., Pérez-García, R., Spanish Registry of Glomerulonephritis. Clinicopathologic correlations of renal pathology in Spain. Kidney Int. 2004;66:898–904.Google Scholar

D’Arrigo, R Tripepi, G., Russo, M. L., et al. Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. Nephrol Dial Transplant. 2020;35:1002–9.Google Scholar

Roos, A., Rastaldi, M. P., Calvaresi, N., et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol. 2006;17:1724–34.Google Scholar

Espinosa, M., Ortega, R., Sánchez, M., Segarra, A.: Spanish Group for Study of Glomerular Diseases (GLOSEN). Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2014;9:897–904.Google Scholar

Lee, S. M. K., Rao, V. M., Franklin, W. A., et al. IgA nephropathy: Morphologic predictors of progressive renal disease. Hum Pathol. 1982;13:314–22. 23.Google Scholar

Haas, M.. Histologic subclassification of IgA nephropathy: A clinicopathologic study of 244 cases. Am J Kid Dis 1997; 29: 829–42.Google Scholar

Haas, M., Verhave, J. C., Liu, Z. H., et al. A multicenter study of the predictive value of crescents in IgA nephropathy. J Am Soc Nephrol. 2017;28:691–701. Published correction appears in J Am Soc Nephrol. 2017;28:1665.Google Scholar

Roberts, I. S.. Pathology of IgA nephropathy. Nat Rev Nephrol. 2014;10:445–54.Google Scholar

Trimarchi, H., Barratt, J., Cattran, D. C., et al. Oxford Classification of IgA nephropathy 2016: An update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017;91:1014–21.Google Scholar

Hastings, M.C., Rizk, D. V., Kiryluk, K., et al. IgA vasculitis with nephritis: Update of pathogenesis with clinical implications. Pediatr Nephrol. 2022;37:719–33.Google Scholar

Blyth, C. C., Robertson, P. W., Rosenberg, A. R.. Post-streptococcal glomerulonephritis in Sydney: A 16-year retrospective review. J Paediatr Child Health. 2007;43:446.Google Scholar

Kanjanabuch, T., Kittikowit, W., Eiam-Ong, S.. An update on acute postinfectious glomerulonephritis worldwide. Nat Rev Nephrol. 2009;5:259–69.Google Scholar

VanDeVoorde, R. G. 3rd. Acute poststreptococcal glomerulonephritis: The most common acute glomerulonephritis. Pediatr Rev. 2015;36:3–12.Google Scholar

Satoskar, A. A., Parikh, S. V., Nadasdy, T.. Epidemiology, pathogenesis, treatment and outcomes of infection-associated glomerulonephritis. Nat Rev Nephrol. 2020;16:32–50.Google Scholar

Nast, C. C.. Infection-related glomerulonephritis: Changing demographics and outcomes. Adv Chronic Kidney Dis. 2012;19:68–75.Google Scholar

Glassock, R. J., Alvarado, A., Prosek, J., et al. Staphylococcus-related glomerulonephritis and poststreptococcal glomerulonephritis: Why defining “post” is important in understanding and treating infection-related glomerulonephritis. Am J Kidney Dis. 2015;65:826–32.Google Scholar

Rodríguez-Iturbe, B., Batsford, S.. Pathogenesis of poststreptococcal glomerulonephritis a century after Clemens von Pirquet. Kidney Int. 2007;71:1094–104.Google Scholar

Satoskar, A. A., Nadasdy, T. S. F., Silva, F. G.. Acute postinfectious glomerulonephritis and glomerulonephritis caused by persistent bacterial infection. In Jennette, J. C., Olson, J. L., Silva, F. G., D’Agati, V. D. (eds) Heptinstall’s Pathology of the Kidney. 7th ed. Philadelphia: Wolters Kluwer. 2014. P. 367–436.Google Scholar

Kambham, N.. Postinfectious glomerulonephritis. Adv Anat Pathol. 2012;19:338–47.Google Scholar

Sotsiou, F., Dimitriadis, G., Liapis, H.. Diagnostic dilemmas in atypical postinfectious glomerulonephritis. Semin Diagn Pathol. 2002;19:146–59.Google Scholar

Sethi, S., Fervenza, F. C., Zhang, Y., et al. Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int. 2013;83;293–9.Google Scholar

Haas, M., Racusen, L. C., Bagnasco, S. M.. IgA-dominant postinfectious glomerulonephritis: A report of 13 cases with common ultrastructural features. Hum Pathol. 2008;39:1309–16.Google Scholar

Nasr, S. H., D’Agati, V. D.. IgA-dominant postinfectious glomerulonephritis: A new twist on an old disease. Nephron Clin Pract. 2011;119:c18–c25; discussion c26.Google Scholar

Haffner, D., Schindera, F., Aschoff, A., et al. The clinical spectrum of shunt nephritis. Nephrol Dial Transplant. 1997;12:1143–8.Google Scholar

Zhou, X. J.. Membranoproliferative glomerulonephritis. In Jennette, J. C., Olson, J. L., Silva, F. G., D’Agati, V. D. (eds) Heptinstall’s Pathology of the Kidney. 7th ed. Philadelphia: Wolters Kluwer. 2014. P. 301–39.Google Scholar

Sethi, S., Fervenza, F. C.. Membranoproliferative glomerulonephritis: A new look at an old entity. N Engl J Med. 2012;366:1119–31.Google Scholar

D’Agati, V. D., Bomback, A. S.. C3 glomerulopathy: What’s in a name? Kidney Int. 2012;82:379–81.Google Scholar

Pickering, M. C., D’Agati, V. D., Nester, C. M., et al. C3 glomerulopathy: Consensus report. Kidney Int. 2013;84(6):1079–89.Google Scholar

Servais, A., Noël, L. H., Frémeaux-Bacchi V & Lesavre P C3 glomerulopathy. Contrib Nephrol. 2013;181:185–93.Google Scholar

Fakhouri, F., Fremeaux-Bacchi, V., Noel, L. H., et al. C3 glomerulopathy: A new classification. Nat Rev Nephrol. 2010;6:494–9.Google Scholar

Sethi, S., Fervenza, F. C., Zhang, Y., et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol. 2011;6:1009–17.Google Scholar

Sethi, S., Nester, C. M., Smith, R. J.. Membranoproliferative glomerulonephritis and C3 glomerulopathy: Resolving the confusion. Kidney Int. 2012;81(5):434–41.Google Scholar

Hou, J., Markowitz, G. S., Herlitz, L. C., et al. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int. 2014;85:450–6.Google Scholar

Smith, R. J. H., Appel, G. B., Blom, A. M., et al. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019;15:129–43.Google Scholar

Gale, D. P., de Jorge, E. G., Cook, H. T., et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet. 2010;376:794–801.Google Scholar

Appel, G. B., Cook, H. T., Hageman, G., et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): An update. J Am Soc Nephrol. 2005;16:1392–403.Google Scholar

Walker, P. D., Ferrario, F., Joh, K., Bonsib, S. M.. Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod Pathol. 2007;20:605–16.Google Scholar

Smith, R. J., Alexander, J., Barlow, P. N., Botto, M., et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol. 2007;18:2447–56.Google Scholar

Nasr, S. H., Valeri, A. M., Appel, G. B., et al. Dense deposit disease: Clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol. 2009;4:22–32.Google Scholar

Lu, D. F., Moon, M., Lanning, L. D., McCarthy, A. M., Smith, R. J.. Clinical features and outcomes of 98 children and adults with dense deposit disease. Pediatr Nephrol. 2012;27:773–81.Google Scholar

Prema, K. S. J., Kurien, A. A., Gopalakrishnan, N., Walker, P. D., Larsen, C. P.. Dense deposit disease: A greatly increased biopsy incidence in India versus the USA. Clin Kidney J. 2019;12:476–82.Google Scholar

Marinozzi, M. C., Roumenina, L. T., Chauvet, S., et al. Anti-factor B and anti-C3b autoantibodies in C3 glomerulopathy and Ig associated membranoproliferative GN. J Am Soc Nephrol. 2017;28:1603–13.Google Scholar

Bomback, A. S., Smith, R. J., Barile, G. R., et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol. 2012;7:748–76.Google Scholar

Zuber, J., Fakhouri, F., Roumenina, L. T., Loirat, C., Fremeaux-Bacchi, V.. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643–57.Google Scholar

Oosterveld, M. J., Garrelfs, M. R., Hoppe, B., et al. Eculizumab in pediatric dense deposit disease. Clin J Am Soc Nephrol. 2015;10:1773–82.Google Scholar

Kasahara, K., Gotoh, Y., Majima, H., Takeda, A., Mizuno, M.. Eculizumab for pediatric dense deposit disease: A case report and literature review. Clin Nephrol Case Stud. 2020;8:96–102.Google Scholar

Zand, L., Lorenz, E. C., Cosio, F. G., et al. Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. J Am Soc Nephrol. 2014;25:1110–17.Google Scholar

Hiraki, L. T., Benseler, S. M., Tyrrell, P. N., et al. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: A longitudinal study. J Pediatr. 2008;152:550–6.Google Scholar

Cooper, G. S., Parks, C. G., Treadwell, E. L., et al. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus 2002;11:161–7.Google Scholar

Lehman, T. J., McCurdy, D. K., Bernstein, B. H., et al. Systemic lupus erythematosus in the first decade of life. Pediatrics. 1989;83:235–9.Google Scholar

Watson, B., Leone, V., Pilkington, C., et al. Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort. Arthritis Rheum. 2012;64:2356–65.Google Scholar

das Chagas Medeiros, M. M., Bezerra, M. C., Braga, F. N., et al. Clinical and immunological aspects and outcome of a Brazilian cohort of 414 patients with systemic lupus erythematosus (SLE): Comparison between childhood-onset, adult-onset, and late-onset SLE. Lupus 2016;25:355–63.Google Scholar

Brunner, H. I., Gladman, D. D., Ibañez, D., et al. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008;58:556–62.Google Scholar

Hersh, A. O., von Scheven, E., Yazdany, J., et al. Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2009;61:13–20.Google Scholar

Hoffman, I. E., Lauwerys, B. R., De Keyser, F., et al. Juvenile-onset systemic lupus erythematosus: Different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis. 2009;68:412–15.Google Scholar

Barsalou, J., Levy, D. M., Silverman, E. D.. An update on childhood-onset systemic lupus erythematosus. Curr Opin Rheumatol. 2013;25:616–22.Google Scholar

Bajema, I. M., Wilhelmus, S., Alpers, C. E., et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: Clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93:789–96.Google Scholar

Sethi, S., Madden, B. J., Debiec, H., et al. Exotosin-1/exotosin-2 associated membranous nephropathy. J Am Soc Nephrol. 2019;30:1123–36.Google Scholar

Zappitelli, M., Duffy, C. M., Bernard, C., Gupta, I. R.. Evaluation of activity, chronicity and tubulointerstitial indices for childhood lupus nephritis. Pediatr Nephrol. 2008;23:83–91.Google Scholar

Mina, R., Abulaban, K., Klein-Gitelman, M. S., Eberhard, B. A.. Validation of the lupus nephritis clinical indices in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2016;68:195–202.Google Scholar

Wenderfer, S. E., Eldin, K. I. W.. Lupus nephritis. Pediatr Clin North Am. 2019;66:87–99.Google Scholar

Oliva-Damaso, N., Payan, J., Oliva-Damaso, E., Pereda, T., Bomback, A. S.. Lupus podocytopathy: An overview. Adv Chronic Kidney Dis. 2019;26:369–75.Google Scholar

Beck, L. H. Jr, Bonegio, R. G., Lambeau, G., et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11–21.Google Scholar

Tomas, N. M., Beck, L. H. Jr, Meyer-Schwesinger, C., et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371:2277–87.Google Scholar

Sethi, S., Debiec, H., Madden, B., et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int. 2020;97:163–74.Google Scholar

Sethi, S., Madden, B. J., Debiec, H., et al. Exotosin-1/exotosin-2 associated membranous nephropathy. J Am Soc Nephrol. 2019;30:1123–36.Google Scholar

Sethi, S., Debiec, H., Madden, B., et al. Semaphorin 3B–associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney Int. 2020;98:1253–64.Google Scholar

Xu, X., Wang, G., Chen, N., et al. Long-term exposure to air pollution and increased risk of membranous nephropathy in China. J Am Soc Nephrol. 2016;27:3739–46.Google Scholar

Sanchez-Rodriguez, E., Southard, C. T., Kiryluk, K.. GWAS-based discoveries in IgA nephropathy, membranous nephropathy, and steroid-sensitive nephrotic syndrome. Clin J Am Soc Nephrol. 2021;16(3):458–66.Google Scholar

Vivarelli, M., Emma, F., Pellé, T., et al. Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies. Kidney Int. 2015;87:602–9.Google Scholar

Debiec, H., Nauta, J., Coulet, F., et al. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet. 2004;364(9441):1252–9.Google Scholar

Cossey, L. N., Walker, P. D., Larsen, C. P.. Phospholipase A2 receptor staining in pediatric idiopathic membranous glomerulopathy. Pediatr Nephrol. 2013;28:2307–11.Google Scholar

Larsen, C. P., Boils, C. L., Cossey, L. N., Sharma, S. G., Walker, P. D.. Clinicopathologic features of membranous-like glomerulopathy with masked IgG kappa deposits. Kidney Int Rep. 2016;24:299–305.Google Scholar

Makker, S. P.. Treatment of membranous nephropathy in children. Semin Nephrol. 2003;23:379–85.Google Scholar

Menon, S., Valentini, R. P.. Membranous nephropathy in children: Clinical presentation and therapeutic approach. Pediatr Nephrol. 2010;25:1419–28.Google Scholar

Malatesta-Muncher, R., Eldin, K. W., Beck, L. H. Jr, Michael, M.. Idiopathic membranous nephropathy in children treated with rituximab: Report of two cases. Pediatr Nephrol. 2018;33:1089–92.Google Scholar

Swartz, S. J., Eldin, K. W., Hicks, M. J.,, et al. Minimal change disease with IgM+ immunofluorescence: A subtype of nephrotic syndrome. Pediatr Nephrol. 2009;24:1187–92.Google Scholar

Zheng, L. P., Wang, H., Zhang, J. J.. Clinical-pathological characteristics of IgM nephropathy in 34 children. Zhongguo Dang Dai Er Ke Za Zhi. 2010;12:338–40.Google Scholar

Mubarak, M., Kazi, J. I, Shakeel, S., Lanewala, A, Hashmi, S., Akhter, F.. Clinicopathologic characteristics and steroid response of IgM nephropathy in children presenting with idiopathic nephrotic syndrome. APMIS. 2011;119:180–6.Google Scholar

Shakeel, S., Mubarak, M., Kazi, J. I., Lanewala, A.. The prevalence and clinicopathological profile of IgM nephropathy in children with steroid-resistant nephrotic syndrome at a single centre in Pakistan. J Clin Pathol. 2012;65:1072–6.Google Scholar

Juozapaite, S., Cerkauskiene, R., Laurinavicius, A., Jankauskiene, A.. The impact of IgM deposits on the outcome of nephrotic syndrome in children. BMC Nephrol. 2017;18:260.Google Scholar

Kanemoto, K., Ito, H., Anzai, M., et al. Clinical significance of IgM and C1q deposition in the mesangium in pediatric idiopathic nephrotic syndrome. J Nephrol. 2013;26:306–14.Google Scholar

Betjes, M. G., Roodnat, J. I.. Resolution of IgM nephropathy after rituximab treatment. Am J Kidney Dis. 2009;53:1059–62.Google Scholar

Myllymaki, J., Saha, H., Mustonen, J., et al. IgM nephropathy: Clinical picture and long-term prognosis. Am J Kidney Dis. 2003;41:343.Google Scholar

Jennette, J. C., Hipp, C. G.. C1q nephropathy: A distinct pathologic entity usually causing nephrotic syndrome. Am J Kidney Dis. 1985;6:103–10.Google Scholar

Jennette, J. C., Hipp, C. G.. Immunohistopathologic evaluation of C1q in 800 renal biopsy specimens. Am J Clin Pathol. 1985;83:415–20.Google Scholar

Markowitz, G. S., Schwimmer, J. A., Stokes, M. B., et al. C1q nephropathy: A variant of focal segmental glomerulosclerosis. Kidney Int. 2003;64:1232–40.Google Scholar

Vizjak, A., Ferluga, D., Rozic, M., et al. Pathology, clinical presentations, and outcomes of C1q nephropathy. J Am Soc Nephrol. 2008;19:2237–44.Google Scholar

Srivastava, T., Chadha, V.. C1q nephropathy presenting as rapidly progressive crescentic glomerulonephritis. Clin Exp Nephrol. 2000;14:976–9.Google Scholar

Mii, A., Shimizu, A., Masuda, Y., et al. Current status and issues of C1q nephropathy. Clin Exp Nephrol. 2009;13:263–74.Google Scholar

Hisano, S., Fukuma, Y., Segawa, Y., et al. Clinicopathologic correlation and outcome of C1q nephropathy. Clin J Am Soc Nephrol. 2008;3:1637–43.Google Scholar

Gunasekara, V. N., Sebire, N. J., Tullus, K.. C1q nephropathy in children: Clinical characteristics and outcome. Pediatr Nephrol. 2014;29:407–13.Google Scholar

Sharman, A., Furness, P., Feehally, J.. Distinguishing C1q nephropathy from lupus nephritis. Nephrol Dial Transplant. 2004;19:1420–6.Google Scholar

Lau, K. K., Gaber, L. W., Santos, N. M. D., Wyatt, R. J.. C1q nephropathy: Features at presentation and outcome. Pediatr Nephrol. 2005;20:744–9.Google Scholar

Fukuma, Y., Hisano, S., Segawa, Y., et al. Clinicopathologic correlation of C1q nephropathy in children. Am J Kidney Dis. 2006;47:412–18.Google Scholar

Hashimoto, S., Ogawa, Y., Ishida, T., et al. Steroid-sensitive nephrotic syndrome associated with positive C1q immunofluorescence. Clin Exp Nephrol. 2004;8:266–9.Google Scholar

Fakhouri, F., Darré, S., Droz, D., et al. Mesangial IgG glomerulonephritis: A distinct type of primary glomerulonephritis. J Am Soc Nephrol. 2002;13:379–87.Google Scholar

Lim, B. J., Hong, S. W., Jeong, H. J.. IgG nephropathy - confusion and overlap with C1q nephropathy. Clin Nephrol. 2009;72:360–5.Google Scholar

Kharroubi, M., Ben Fatma, L., Rais, L., Jebali, H., Mami, I., Zouaghi, M. K.. Primary glomerulonephritis with predominant mesangial immunoglobulin G deposits. Tunis Med. 2018;96:442–4.Google Scholar

Jourde-Chiche, N., Moal, V., Daniel, L., Purgus, R.. Early IgG glomerulonephritis recurrence in a kidney transplant recipient. Clin Nephrol. 2008;70:340–3.Google Scholar

References

Grabowski, G. A., Desnick, R. J., Ludman, M. D., Kafonek, S. D., Kwiterovich, P. O., Bernstein, J.. The kidney in metabolic disorders. In Edelmann, CM, Bernstein, J, Meadow, SR eds. Pediatric Kidney Disease. 2nd ed. Little, Brown; 1992. P. 1599–623.Google Scholar

Emma, F., van’t Hoff, W. G., Dionisi Vici, C.. Renal manifestations of metabolic disorders in children. In Avner, E, Harmon, W, Niaudet, P, Yoshikawa, N, Emma, F, Goldstein, S eds. Pediatric Nephrology. Springer, Berlin, Heidelberg; 2016. P 1569–607.Google Scholar

Groth, C. G., Ringdén, O. Transplantation in relation to the treatment of inherited disease. Transplantation. 1984;38:319–27.Google Scholar

Kayler, L. K., Merion, R. M., Lee, S., Sung, R. S., Punch, J. D., Rudich, S. M., et al. Long-term survival after liver transplantation in children with metabolic disorders. Pediatr Transplant. 2002;6:295–300.Google Scholar

Sirac, C., Bridoux, F., Essig, M., Devuyst, O., Touchard, G., Cogné, M.. Toward understanding renal Fanconi syndrome: Step by step advances through experimental models. Contrib Nephrol. 2011;169:247–61.Google Scholar

Finn, L. S.. Renal disease caused by inborn errors of metabolism, storage diseases, and hemoglobinopathies. In: Jennette, JC, D’Agati, VD, Olson, JL, Silva, FG eds. Heptinstall’s Pathology of the Kidney. 7th ed. Wolters Kluwer Health; 2015. P 1223–78.Google Scholar

Ferreira, C. R., Gahl, W. A.. Lysosomal storage diseases. Transl Sci Rare Dis. 2017;2:1–71.Google Scholar

Faraggiana, T., Churg, J.. Renal lipidoses: A review. Hum Pathol. 1987;18:661–79.Google Scholar

Hicks, J., Wartchow, E., Mierau, G.. Glycogen storage diseases: A brief review and update on clinical features, genetic abnormalities, pathologic features, and treatment. Ultrastruct Pathol. 2011;35:183–96.Google Scholar

Eikrem, Ø., Skrunes, R., Tøndel, C., Leh, S., Houge, G., Svarstad, E., et al. Pathomechanisms of renal Fabry disease. Cell Tissue Res. 2017;369:53–62.Google Scholar

Tondel, C., Bostad, L., Hirth, A., Svarstad, E.. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis. 2008;51:767–76.Google Scholar

Laney, D. A., Peck, D. S., Atherton, A. M., Manwaring, L. P., Christensen, K. M., Shankar, S. P., et al. Fabry disease in infancy and early childhood: A systematic literature review. Genet Med. 2015;17:323–30.Google Scholar

Nowak, A., Mechtler, T. P., Hornemann, T., Gawinecka, J., Theswet, E., Hilz, M. J., et al. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease. Mol Genet Metab. 2018;123:148–53.Google Scholar

Najafian, B., Svarstad, E., Bostad, L., Gubler, M. C., Tondel, C., Whitley, C., et al. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int. 2011;79:663–70.Google Scholar

Chimenz, R., Chirico, V., Cuppari, C., Ceravolo, G., Concolino, D., Monardo, P., et al. Fabry disease and kidney involvement: Starting from childhood to understand the future. Pediatr Nephrol. 2022;37:95–103.Google Scholar

Thurberg, B. L., Rennke, H., Colvin, R. B., Dikman, S., Gordon, R. E., Collins, A. B., et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 2002;62:1933–46.Google Scholar

Barisoni, L., Jennette, J. C., Colvin, R., Sitaraman, S., Bragat, A., Castelli, J., et al. Novel quantitative method to evaluate globotriaosylceramide inclusions in renal peritubular capillaries by virtual microscopy in patients with fabry disease. Arch Pathol Lab Med. 2012;136:816–24.Google Scholar

Fogo, A. B., Bostad, L., Svarstad, E., Cook, W. J., Moll, S., Barbey, F., et al. Scoring system for renal pathology in Fabry disease: Report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant. 2010;25:2168–77.Google Scholar

Skrunes, R., Tondel, C., Leh, S., Larsen, K. K., Houge, G., Davidsen, E. S., et al. Long-term dose-dependent agalsidase effects on kidney histology in Fabry disease. Clin J Am Soc Nephrol. 2017;12:1470–9.Google Scholar

Bracamonte, E. R., Kowalewska, J., Starr, J., Gitomer, J., Alpers, C. E.. Iatrogenic phospholipidosis mimicking Fabry disease. Am J Kidney Dis. 2006;48:844–50.Google Scholar

Lei, L., Oh, G., Sutherland, S., Abra, G., Higgins, J., Sibley, R., et al. Myelin bodies in LMX1B-associated nephropath: potential for misdiagnosis. Pediatr Nephrol. 2020;35:1647–57.Google Scholar

Spada, M., Baron, R., Elliott, P. M., Falissard, B., Hilz, M. J., Monserrat, L., et al. The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease: A systematic literature review by a European panel of experts. Mol Genet Metab. 2019;126:212–23.Google Scholar

McGovern, M. M., Wasserstein, M. P., Giugliani, R., Bembi, B., Vanier, M. T., Mengel, E., et al. A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B. Pediatrics. 2008;122:e341–9.Google Scholar

Takebayashi, S., von Bassewitz, D. B., Themann, H.. Ultrastructural alterations of the kidney in generalized gangliosidosis GM1. Virchows Arch B Cell Pathol. 1970;5:301–13.Google Scholar

Annunziata, I., d’Azzo, A.. Galactosialidosis: Historic aspects and overview of investigated and emerging treatment options. Expert Opin Orphan Drugs. 2017;5:131–41.Google Scholar

Majno, G., Joris, I.. Cells, Tissues, and Disease: Principles of General Pathology. 2nd ed. Oxford University Press: New York; 2004. P. 145–54.Google Scholar

Olkkonen, V. M., Ikonen, E.. Genetic defects of intracellular-membrane transport. N Engl J Med. 2000;343:1095–104.Google Scholar

Plante, M., Claveau, S., Lepage, P., Lavoi, E. M., Brunet, S., Roquis, D., et al. Mucolipidosis II: A single causal mutation in the N-acetylglucosamine-1-phosphotransferase gene (GNPTAB) in a French Canadian founder population. Clin Genet. 2008;73:236–44.Google Scholar

Okada, S., Owada, M., Sakiyama, T., Yutaka, T., Ogawa, M.. I-cell disease: Clinical studies of 21 Japanese cases. Clin Genet. 1985;28:207–15.Google Scholar

Khan, S. A., Tomatsu, S. C.. Mucolipidoses overview: Past, present, and future. Int J Mol Sci. 2020;21(18).Google Scholar

Renwick, N., Nasr, S. H., Chung, W. K., Garvin, J., Markowitz, G. S., Marboe, C., et al. Foamy podocytes. Am J Kidney Dis. 2003;41(4):891–6.Google Scholar

Tüysüz, B., Ercan-Sencicek, A. G., Canpolat, N., Koparır, A., Yılmaz, S., Kılıçaslan, I., et al. Renal involvement in patients with mucolipidosis IIIalpha/beta: Causal relation or co-occurrence? Am J Med Genet A. 2016;170a:1187–95.Google Scholar

Hu, J., Lu, J. Y., Wong, A. M., Hynan, L. S., Birnbaum, S. G., Yilmaz, D. S., et al. Intravenous high-dose enzyme replacement therapy with recombinant palmitoyl-protein thioesterase reduces visceral lysosomal storage and modestly prolongs survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis. Mol Genet Metab. 2012;107:213–21.Google Scholar

Meng, Y., Sohar, I., Wang, L., Sleat, D. E., Lobel, P.. Systemic administration of tripeptidyl peptidase I in a mouse model of late infantile neuronal ceroid lipofuscinosis: Effect of glycan modification. PLoS ONE. 2012;7:e40509.Google Scholar

Järvelä, I., Lehtovirta, M., Tikkanen, R., Kyttälä, A., Jalanko, A.. Defective intracellular transport of CLN3 is the molecular basis of Batten disease (JNCL). Hum Mol Genet. 1999;8:1091–8.Google Scholar

Golubek, A. A., Kida, E., Walus, M., Kaczmarski, W., Wujek, P., Wisniewski, K.. CLN3 disease process: Missense point mutations and protein depletion in vitro. Eur J Paediatr Neurol. 2001;5 (Suppl A):81–8.Google Scholar

Saito, T., Matsunaga, A., Fukunaga, M., Nagahama, K., Hara, S., Muso, E.. Apolipoprotein E-related glomerular disorders. Kidney Int. 2020;97:279–88.Google Scholar

Kawanishi, K., Sawada, A., Ochi, A., Moriyama, T., Mitobe, M., Mochizuki, T., et al. Glomerulopathy with homozygous apolipoprotein e2: A report of three cases and review of the literature. Case Rep Nephrol Urol. 2013;3:128–35.Google Scholar

Saito, T., Sato, H., Kudo, K., Oikawa, S., Shibata, T., Hara, Y., et al. Lipoprotein glomerulopathy: Glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. Am J Kidney Dis. 1989;13:148–53.Google Scholar

Hu, Z., Huang, S., Wu, Y., Liu, Y., Liu, X., Su, D., et al. Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation. Kidney Int. 2014;85:416–24.Google Scholar

Saito, T., Oikawa, S., Sato, H., Sato, T., Ito, S., Sasaki, J.. Lipoprotein glomerulopathy: Significance of lipoprotein and ultrastructural features. Kidney Int Suppl. 1999;71:S37–41.Google Scholar

Norum, K. R., Remaley, A. T., Miettinen, H. E., Strøm, E. H., Balbo, B. E. P., Sampaio, C., et al. Lecithin:cholesterol acyltransferase: Symposium on 50 years of biomedical research from its discovery to latest findings. J Lipid Res. 2020;61:1142–9.Google Scholar

Ossoli, A., Neufeld, E. B., Thacker, S. G., Vaisman, B., Pryor, M., Freeman, L. A., et al. Lipoprotein X causes renal disease in LCAT deficiency. PLoS ONE. 2016;11:e0150083.Google Scholar

Holleboom, A. G., Kuivenhoven, J. A., van Olden, C. C., Peter, J., Schimmel, A. W., Levels, J. H., et al. Proteinuria in early childhood due to familial LCAT deficiency caused by loss of a disulfide bond in lecithin:cholesterol acyl transferase. Atherosclerosis. 2011;216:161–5.Google Scholar

Saeedi, R., Li, M., Frohlich, J.. A review on lecithin:cholesterol acyltransferase deficiency. Clin Biochem. 2015;48:472–5.Google Scholar

Pavanello, C., Ossoli, A., Arca, M., D’Erasmo, L., Boscutti, G., Gesualdo, L., et al. Progression of chronic kidney disease in familial LCAT deficiency: A follow-up of the Italian cohort. J Lipid Res. 2020;61:1784–8.Google Scholar

Strøm, E. H., Sund, S., Reier-Nilsen, M., Dørje, C, Leren, T. P.. Lecithin:cholesterol acyltransferase (LCAT) deficiency: Renal lesions with early graft recurrence. Ultrastruct Pathol. 2011;35:139–45.Google Scholar

Kamath, B. M., Podkameni, G., Hutchinson, A. L., Leonard, L. D., Gerfen, J., Krantz, I. D., et al. Renal anomalies in Alagille syndrome: A disease-defining feature. Am J Med Genet A. 2012;158a:85–9.Google Scholar

Bissonnette, M. L. Z., Lane, J. C., Chang, A.. Extreme renal pathology in Alagille syndrome. Kidney Int Rep. 2016;2:493–7.Google Scholar

Franceschetti, S., Canafoglia, L.. Sialidoses. Epileptic Disord. 2016;18(S2):89–93.Google Scholar

Maroofian, R., Schuele, I., Najafi, M., Bakey, Z., Rad, A., Antony, D., et al. Parental whole-exome sequencing enables sialidosis type II diagnosis due to an NEU1 missense mutation as an underlying cause of nephrotic syndrome in the child. Kidney Int Rep. 2018;3:1454–63.Google Scholar

Khan, A., Sergi, C.. Sialidosis: A review of morphology and molecular biology of a rare pediatric disorder. Diagnostics (Basel). 2018;8:9.Google Scholar

Chen, W., Yang, S., Shi, H., Guan, W., Dong, Y., Wang, Y., et al. Histological studies of renal biopsy in a boy with nephrosialidosis. Ultrastruct Pathol. 2011;35:168–71.Google Scholar

Sláma, T., Garbade, S. F., Kölker, S., Hoffmann, G. F., Ries, M.. Quantitative natural history characterization in a cohort of 142 published cases of patients with galactosialidosis-A cross-sectional study. J Inherit Metab Dis. 2019;42:295–302.Google Scholar

Ketterer, S., Gomez-Auli, A., Hillebrand, L. E., Petrera, A., Ketscher, A., Reinheckel, T.. Inherited diseases caused by mutations in cathepsin protease genes. FEBS J. 2017;284:1437–54.Google Scholar

Hicks, J., Wartchow, E., Mierau, G.. Glycogen storage diseases: A brief review and update on clinical features, genetic abnormalities, pathologic features, and treatment. Ultrastruct Pathol. 2011;35:183–96.Google Scholar

Martens, D. H., Rake, J. P., Navis, G., Fidler, V., van Dael, C. M., Smit, G. P.. Renal function in glycogen storage disease type I, natural course, and renopreservative effects of ACE inhibition. Clin J Am Soc Nephrol. 2009;4:1741–6.Google Scholar

Chen, Y. T.. Type I glycogen storage disease: Kidney involvement, pathogenesis and its treatment. Pediatr Nephrol. 1991;5:71–6.Google Scholar

de Lonlay, P., Seta, N., Barrot, S., Chabrol, B., Drouin, V., Gabriel, B. M., et al. A broad spectrum of clinical presentations in congenital disorders of glycosylation I: A series of 26 cases. J Med Genet. 2001;38(1):14–19.Google Scholar

Sinha, M. D., Horsfield, C., Komaromy, D., Booth, C. J., Champion, M. P.. Congenital disorders of glycosylation: A rare cause of nephrotic syndrome. Nephrol Dial Transplant. 2009;24:2591–4.Google Scholar

Marcovecchia, M. L., Chiarelli, F.. Diabetic nephropathy in children. In Avner, E, Harmon, W, Niaudet, P, Yoshikawa, N, Emma, F, Goldstein, S eds. Pediatric Nephrology. Springer, Berlin, Heidelberg; 2016. P1545–68.Google Scholar

Reinehr, T.. Type 2 diabetes mellitus in children and adolescents. World J Diabetes. 2013;4:270–81.Google Scholar

Dabelea, D., Mayer-Davis, E. J., Saydah, S., Imperatore, G., Linder, B., Divers, J., et al. Prevance of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA. 2014;311:1778–86.Google Scholar

Gross, J. L., de Azevedo, M. J., Silviero, S. P., Canani, L. H., Caramori, M. L., Zelmanowitz, T.. Diabetic nephropathy: Diagnosis, prevention and treatment. Diabetes Care. 2005;28:164–76.Google Scholar

Mokha, J. S., Srinivasan, S. R., Dasmahapatra, P., Fernandez, C., Chen, W., Xu, J., et al. Utility of waist-to-height ratio in assessing the status of central obesity and related cardiometabolic risk profile among normal weight and overweight/obese children: The Bogalusa Heart Study. BMC Pediatr. 2010;10:73.Google Scholar

Ford, E. S., Li, C.. Defining the metabolic syndrome in children and adolescents. J Pediatr. 2008;152:160–4.Google Scholar

Lee, S., Bacha, F., Gungo, N., Arslanian, S.. Comparison of different definitions of pediatric metabolic syndrome: Relation to abdominal adiposity, insulin resistance, adiponectin, and inflammatory biomarkers. J Pediatr. 2008;152:177–84.Google Scholar

Sanad, M., Gharib, A.. Evaluation of microalbuminuria in obese children and its relation to metabolic syndrome. Pediatr Nephrol. 2011;26:2193–9.Google Scholar

Baumgartner, M. R., Horster, F., Dionosi-Vici, C., Haliloglu, G., Karall, D., Chapman, K. A., et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014;9:130.Google Scholar

Cosson, M. A., Benoist, J. F., Touati, G., Déchaux, M., Royer, N., Grandin, L., et al. Long-term outcome in methylmalonic aciduria: A series of 30 French patients. Mol Genet Metab. 2009;97:172–8.Google Scholar

Ha, T. S., Lee, J. S., Hing, E. J.. Delay of renal progression in methylmalonic acidurias using angiotensin II inhibitors: A case report. J Nephrol. 2008;21:793–6.Google Scholar

Gaines, J. J.. The pathology of alkaptonuric ochronosis. Hum Pathol. 1989;20:40–6.Google Scholar

Venkataseshan, V. S., Chandra, B., Graziano, V., Steinlauf, P., Marquet, E., Irmiere, V., et al. Alkaptonuria and renal failure: A case report and review of literature. Mod Pathol. 1992;5:464–71.Google Scholar

Malowany, J. I., Butany, J.. Pathology of sickle cell disease. Semin Diagn Pathol. 2012;29:49–55.Google Scholar

Modell, B., Darlison, M.. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86:480–7.Google Scholar

Pham, P. T., Pham, P. C., Wilkinson, A. H., Lew, S. Q.. Renal abnormalities in sickle cell disease. Kidney Int. 2000;57:1–8.Google Scholar

Wigfall, D. R., Ware, R. E., Burchinal, M. R., Kinney, T. R., Foreman, J. W.. Prevalence and clinical correlates of glomerulopathy in children with sickle cell disease. J Pediatr. 2000;136:749–53.Google Scholar

McPherson Yee, M., Jabbar, S. F., Osunkwo, I., Clement, L., Lane, P. A., Eckman, J. R., et al. Chronic kidney disease and albuminuria in children with sickle cell disease. Clin J Am Soc Nephrol. 2011;6:2628–33.Google Scholar

References

Kyle, R. A.. Amyloidosis: A convoluted story. Br J Haematol. 2001;114:529–38.Google Scholar

Hashkes, P. J.. 50 years ago in The Journal of Pediatrics: Amyloidosis in childhood. J Pediatr. 2019;205:54.Google Scholar

Rowczenio, D., Stensland, M., de Souza, G. A., et al. Renal amyloidosis associated with 5 novel variants in the fibrinogen A alpha chain protein. Kidney Int Rep. 2017;2:461–9.Google Scholar

Palsdottir, A., Snorradottir, A. O., Thorsteinsson, L.. Hereditary cystatin C amyloid angiopathy: Genetic, clinical, and pathological aspects. Brain Pathol. 2006;16:55–9.Google Scholar

Bilginer, Y., Akpolat, T., Ozen, S.. Renal amyloidosis in children. Pediatr Nephrol. 2011;26:1215–27.Google Scholar

Alzyoud, R., Alsweiti, M., Maittah, H., et al. Familial Mediterranean fever in Jordanian children: Single centre experience. Mediterr J Rheumatol. 2018;29:211–16.Google Scholar

Gattorno, M., Hofer, M., Federici, S., et al. Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis. 2019;78:1025–32.Google Scholar

Yazılıtaş, F., Çakıcı, E. K., Kurt Şükür, E. D., et al. Clinicopathological assessment of kidney biopsies in children with familial Mediterranean fever: A single-center experience. Nephron. 2020;144:222–7.Google Scholar

Westermark, G. T., Fändrich, M., Westermark, P.. AA amyloidosis: Pathogenesis and targeted therapy. Ann Rev Pathol. 2015;10:321–44.Google Scholar

Garg, N., Jain, S., Chauhan, S., et al. Clinicopathological spectrum of renal amyloidosis in young. Saudi J Kidney Dis Transpl. 2020;31:1085–90.Google Scholar

Kang, H. G., Bybee, A., Ha, I. S., et al. Hereditary amyloidosis in early childhood associated with a novel insertion-deletion (indel) in the fibrinogen Aalpha chain gene. Kidney Int. 2005;68:1994–8.Google Scholar

Wechalekar, A. D., Gillmore, J. D., Hawkins, P. N.. Systemic amyloidosis. Lancet. 2016;387:2641–54.Google Scholar

Kidd, J., Carl, D. E.. Renal amyloidosis. Curr Probl Cancer. 2016;40:209–19.Google Scholar

Gupta, A., Bagri, N. K., Tripathy, S. K., et al. Successful use of tocilizumab in amyloidosis secondary to systemic juvenile idiopathic arthritis. Rheumatol Int. 2020;40:153–9.Google Scholar

Shen, Y., Meunier, L., Hendershot, L. M.. Identification and characterization of a novel endoplasmic reticulum (ER) DnaJ homologue, which stimulates ATPase activity of BiP in vitro and is induced by ER stress. J Biol Chem. 2002;277:15947–56.Google Scholar

Klomjit, N., Alexander, M. P., Zand, L.. Fibrillary glomerulonephritis and DnaJ homolog subfamily B member 9 (DNAJB9). Kidney360. 2020;1:1002–13.Google Scholar

Nasr, S. H., Fogo, A. B.. New developments in the diagnosis of fibrillary glomerulonephritis. Kidney Int. 2019;96:581–92.Google Scholar

Dasari, S., Alexander, M. P., Vrana, J. A., et al. DnaJ heat shock protein family B member 9 is a novel biomarker for fibrillary GN. J Am Soc Nephrol. 2018;29:51–6.Google Scholar

Bazina, M., Glavina-Durdov, M., Sćukanec-Spoljar, M., et al. Epidemiology of renal disease in children in the region of southern Croatia: A 10-year review of regional renal biopsy databases. Med Sci Monit. 2007;13:Cr172–6.Google Scholar

Menon, S., Zeng, X., Valentini, R.. Fibrillary glomerulonephritis and renal failure in a child with systemic lupus erythematosus. Pediatr Nephrol. 2009;24:1577–81.Google Scholar

Nasr, S. H., Valeri, A. M., Cornell, L. D., et al. Fibrillary glomerulonephritis: A report of 66 cases from a single institution. Clin J Am Soc Nephrol. 2011;6:775–84.Google Scholar

Rosenstock, J. L., Markowitz, G. S., Valeri, A. M., et al. Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features. Kidney Int. 2003;63:1450–61.Google Scholar

Said, S. M., Leung, N., Alexander, M. P., et al. DNAJB9-positive monotypic fibrillary glomerulonephritis is not associated with monoclonal gammopathy in the vast majority of patients. Kidney Int. 2020;98:498–504.Google Scholar

Bahrami, D., Henegar, J. R., Baliga, R.. Fibrillary glomerulopathy in a 10-year-old female. Pediatr Nephrol. 2001;16:916–18.Google Scholar

Bircan, Z., Toprak, D., Kilicaslan, I., et al. Factor H deficiency and fibrillary glomerulopathy. Nephrol Dial Transplant. 2004;19:727–30.Google Scholar

Shim, Y. H., Lee, S. J., Sung, S. H.. A case of fibrillary glomerulonephritis with unusual IgM deposits and hypocomplementemia. Pediatr Nephrol. 2008;23:1163–6.Google Scholar

Takemura, T., Yoshioka, K., Akano, N., et al. Immunotactoid glomerulopathy in a child with Down syndrome. Pediatr Nephrol. 1993;7:86–8.Google Scholar

Andeen, N. K., Troxell, M. L., Riazy, M., et al. Fibrillary glomerulonephritis: Clinicopathologic features and atypical cases from a multi-institutional cohort. Clin J Am Soc Nephrol. 2019;14:1741–50.Google Scholar

Alexander, M. P., Dasari, S., Vrana, J. A., et al. Congophilic fibrillary glomerulonephritis: A case series. Am J Kidney Dis. 2018;72:325–36.Google Scholar

Nasr, S. H., Vrana, J. A., Dasari, S., et al. DNAJB9 is a specific immunohistochemical marker for fibrillary glomerulonephritis. Kidney Int Rep. 2018;3:56–64.Google Scholar

Collins, M., Navaneethan, S. D., Chung, M., et al. Rituximab treatment of fibrillary glomerulonephritis. Am J Kidney Dis. 2008;52:1158–62.Google Scholar

Hogan, J., Restivo, M., Canetta, P. A., et al. Rituximab treatment for fibrillary glomerulonephritis. Nephrol Dial Transplant. 2014;29:1925–31.CrossRef Google Scholar PubMed

Lusco, M. A., Chen, Y. P., Cheng, H., et al. AJKD atlas of renal pathology: Fibronectin glomerulopathy. Am J Kidney Dis. 2017;70:e21–e2.Google Scholar

Strøm, E. H., Banfi, G., Krapf, R., et al. Glomerulopathy associated with predominant fibronectin deposits: A newly recognized hereditary disease. Kidney Int. 1995;48:163–70.Google Scholar

Niimi, K., Tsuru, N., Uesugi, N., et al. Fibronectin glomerulopathy with nephrotic syndrome in a 3-year-old male. Pediatr Nephrol. 2002;17:363–6.Google Scholar

Castelletti, F., Donadelli, R., Banterla, F., et al. Mutations in FN1 cause glomerulopathy with fibronectin deposits. Proc Natl Acad Sci U S A. 2008;105:2538–43.Google Scholar

Satoskar, A. A., Shapiro, J. P., Bott, C. N., et al. Characterization of glomerular diseases using proteomic analysis of laser capture microdissected glomeruli. Mod Pathol. 2012;25:709–21.Google Scholar

Gemperle, O., Neuweiler, J., Reutter, F. W., et al. Familial glomerulopathy with giant fibrillar (fibronectin-positive) deposits: 15-year follow-up in a large kindred. Am J Kidney Dis. 1996;28:668–75.Google Scholar

Otsuka, Y., Takeda, A., Horike, K., et al. A recurrent fibronectin glomerulopathy in a renal transplant patient: A case report. Clin Transplant. 2012;26 Suppl 24:58–63.Google Scholar

Alchi, B., Nishi, S., Narita, I., et al. Collagenofibrotic glomerulopathy: Clinicopathologic overview of a rare glomerular disease. Am J Kidney Dis. 2007;49:499–506.Google Scholar

Imbasciati, E., Gherardi, G., Morozumi, K., et al. Collagen type III glomerulopathy: A new idiopathic glomerular disease. Am J Nephrol. 1991;11:422–9.Google Scholar

References

DiMauro, S., Schon, E. A.. Mitochondrial respiratory-chain diseases. N Engl J Med 2003;348:2656–68.Google Scholar

Luo, S., Valencia, C. A., Zhang, J., et al. Biparental inheritance of mitochondrial DNA in humans. Proc Natl Acad Sci U S A 2018;115:13039–44.Google Scholar

Koenig, M. K.. Presentation and diagnosis of mitochondrial disorders in children. Pediatr Neurol 2008;38:305–13.Google Scholar

Thorburn, D. R.. Mitochondrial disorders: Prevalence, myths and advances. J Inherit Metab Dis 2004;27:349–62.Google Scholar

Stewart, J. B., Chinnery, P. F.. The dynamics of mitochondrial DNA heteroplasmy: Implications for human health and disease. Nat Rev Genet 2015;16:530–42.Google Scholar

Rahman, S.. Mitochondrial disease in children. J Intern Med 2020;287:609–33.Google Scholar

Govers, L. P., Toka, H. R., Hariri, A., et al. Mitochondrial DNA mutations in renal disease: An overview. Pediatr Nephrol 2021;36:9–17.Google Scholar

Schon, E. A., DiMauro, S., Hirano, M.. Human mitochondrial DNA: Roles of inherited and somatic mutations. Nat Rev Genet 2012;13:878–90.Google Scholar

Emma, F., Montini, G., Salviati, L., Dionisi-Vici, C.. Renal mitochondrial cytopathies. Int J Nephrol 2011;2011:609213.Google Scholar

Emma, F., Montini, G., Parikh, S. M., Salviati, L.. Mitochondrial dysfunction in inherited renal disease and acute kidney injury. Nat Rev Nephrol 2016;12:267–80.Google Scholar

O’Toole, J. F.. Renal manifestations of genetic mitochondrial disease. Int J Nephrol Renovasc Dis 2014;7:57–67.Google Scholar

Niaudet, P.. Mitochondrial disorders and the kidney. Arch Dis Child 1998;78:387–90.Google Scholar

De Vriese, A. S., Sethi, S., Nath, K. A., et al. Differentiating primary, genetic, and secondary FSGS in adults: A clinicopathologic approach. J Am Soc Nephrol 2018;29:759–74.Google Scholar

Lee, H. N., Eom, S., Kim, S. H., et al. Epilepsy characteristics and clinical outcome in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS). Pediatr Neurol 2016;64:59–65.Google Scholar

Di Donato, S.. Multisystem manifestations of mitochondrial disorders. J Neurol 2009;256:693–710.Google Scholar

Jansen, J. J., Maassen, J. A., Van Der Woude, F. J., et al. Mutation in mitochondrial tRNALeu(UUR) gene associated with progressive kidney disease. J Am Soc Nephrol 1997;8:1118–24.Google Scholar

Guery, B., Choukroun, G., Noel, L. H., et al. The spectrum of systemic involvement in adults presenting with renal lesion and mitochondrial tRNA(Leu) gene mutation. J Am Soc Nephrol 2003;14:2099–108.Google Scholar

Hirano, M., Konishi, K., Arata, N., et al. Renal complications in a patient with A-to-G mutation of mitochondrial DNA at the 3243 position of leucine tRNA. Intern Med 2002;41:113–18.Google Scholar

Fervenza, F. C., Gavrilova, R. H., Nasr, S. H., et al. CKD due to a novel mitochondrial DNA mutation: A case report. Am J Kidney Dis 2019;73:273–7.Google Scholar

Connor, T. M., Hoer, S., Mallett, A., et al. Mutations in mitochondrial DNA causing tubulointerstitial kidney disease. PLoS Genet 2017;13:e1006620.Google Scholar

Diomedi-Camassei, F., Di Giandomenico, S., Santorelli, F. M., et al. COQ2 nephropathy: A newly described inherited mitochondriopathy with primary renal involvement. J Am Soc Nephrol 2007;18:2773–80.Google Scholar

Emma, F., Salviati, L.. Mitochondrial cytopathies and the kidney. Nephrol Ther 2017;13 Suppl 1:S23–S8.Google Scholar

Hotta, O., Inoue, C. N., Miyabayashi, S., et al. Clinical and pathologic features of focal segmental glomerulosclerosis with mitochondrial tRNALeu(UUR) gene mutation. Kidney Int 2001;59:1236–43.Google Scholar

Starr, M. C., Chang, I. J., Finn, L. S., et al. COQ2 nephropathy: A treatable cause of nephrotic syndrome in children. Pediatr Nephrol 2018;33:1257–61.Google Scholar

Slone, J., Huang, T.. The special considerations of gene therapy for mitochondrial diseases. NPJ Genom Med 2020;5:7.Google Scholar

Torres-Torronteras, J., Cabrera-Perez, R., Vila-Julia, F., et al. Long-term sustained effect of liver-targeted adeno-associated virus gene therapy for mitochondrial neurogastrointestinal encephalomyopathy. Hum Gene Ther 2018;29:708–18.Google Scholar

Book contents

Section 2 - Glomerular Diseases

Summary

Access options

References

References

References

References

References

References

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive